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Abstract 
Breast cancer is the most common malignancy in women worldwide. 
Deregulations of members of the ErbB receptor family play an important role in 
breast cancer pathogenesis. Epidermal growth factor (EGF) binds to EGF 
receptor (EGFR) and activates a network of signalling pathways. The two major 
downstream signalling pathways of EGFR are the mitogen-activated protein 
kinase(MAPK)- and the phosphoinositide 3-kinase(PI3K)-transduction systems. 
Both pathways exhibit a high frequency of activating mutations and are good 
targets for cancer therapy.  
Two irreversible ErbB inhibitors termed pelitinib and canertinib were tested in 
breast cancer cell lines. In some cell lines the drugs showed good growth 
inhibitory effects but there were still some cell lines, which were highly resistant 
to treatment with these drugs. In this study we concentrated on the two breast 
cancer cell lines SKBR3 and T47D, which proved to be resistant and sensitive 
to ErbB inhibition respectively. By treatment of SKBR3 and T47D cell lines with 
PI3K and MAPK pathway inhibitors we examined the significance of both 
pathways for growth of these cell lines and for the development of resistance 
against ErbB inhibitory drugs. We applied mTOR-(rapamycin), AKT-(Akti-1,2) 
and PI3K/mTOR-(NVP-BEZ 235) inhibitors to examine the PI3K/AKT pathway 
and MEK1,2 (AZD6244, U0126 and AS703026) inhibitors to silence the MAPK 
pathway. Results showed that in vitro growth of both cell lines was highly 
sensitive to inhibition by PI3K/AKT pathway inhibitors, especially to NVP-BEZ 
235, but resistant to MAPK pathway inhibition. This finding let us suggest that 
the PI3K/AKT pathway plays a more important role in growth of these cell lines 
and could be a good target to overcome resistance against ErbB inhibition. Our 
assumption could be confirmed by a combined therapy using canertinib or 
pelitinib together with PI3K/AKT pathway inhibitors, which leads to a strong 
decrease of the ErbB drug resistance. Of note, this therapy showed especially 
good growth inhibitory effects by combination of ErbB inhibitors with NVP-BEZ 
235, the dual PI3K and mTOR inhibitor. On the other hand, our data reveal that 
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inhibition of the MAPK pathway did not have any growth inhibitory effect. In 
contrast, the data indicate that an ErbB independent activation of the PI3K/AKT 
pathway is a very important determinant, for resistance against the ErbB 
inhibitors pelitnib and canertinib. 
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Zusammenfassung 
Brustkrebs ist die häufigste Krebserkrankung bei Frauen weltweit. Die ErbB 
Rezeptor Familie spielt eine wichtige Rolle in der Entstehung dieser 
Erkrankung. Sie zeigt sehr oft eine Deregulierung in Krebserkrankungen. Der 
epidermale Wachstumsfaktor (EGF) bindet am EGF Rezeptor (EGFR) und 
aktiviert ein Netzwerk von Signalwegen. Die zwei bedeutendsten 
nachgeschalteten Signalwege von EGFR sind der mitogen aktivierte 
Proteinkinase (MAPK)- und der Phosphoinositide 3-kinase (PI3K)- Weg. Beide 
Signalwege weisen eine hohe Frequenz an Mutationen auf und sind daher gute 
Ziele für die Krebstherapie. 
Der Effekt von zwei irreversiblen ErbB Inhibitoren genannt Pelitinib und 
Canertinib wurde in Brustkrebszelllinien getestet. In einigen Zellen zeigten sie 
gute wachstumsinhibierende Effekte, jedoch gibt es immer noch einige, die 
resistent auf eine Behandlung mit diesen Substanzen reagieren. In unserer 
Studie haben wir uns auf zwei bestimmte Brustkrebszelllinien, SKBR3 und 
T47D, konzentriert, die resistent und sensitiv auf ErbB Inhibierung reagieren. 
Durch Behandlung von SKBR3 und T47D Zelllinien mit PI3K- und MAPK-
Signalweginhibitoren wollten wir die Bedeutung beider Signalwege für diese 
Zelllinien untersuchen und darüber hinaus die Mechanismen der Resistenz 
definieren. Wir haben mTOR-(Rapamycin), AKT-(Akti-1,2) und PI3K/mTOR-
(NVP-BEZ 235) Inhibitoren angewandt um den PI3K/AKT Signalweg und 
MEK1,2 (AZD6244, U0126 und AS703026) Inhibitoren um den MAPK 
Signalweg zu bestimmen. Die Ergebnisse zeigten, dass beide Zelllinien sehr 
gut auf eine Inhibierung mit PI3K/AKT Signalweginhibitoren, besonders mit 
NVP-BEZ 235, aber in sehr schlechtem Ausmaß auf eine MAPK 
Signalweginhibierung ansprechen. Diese Erkenntnisse ließen uns vermuten 
dass der PI3K/AKT Signalweg eine wichtigere Rolle in diesen Zelllinien spielt 
und eine sehr gute Zielstruktur wäre, um die Resistenz gegen ErbB Inhibierung 
zu überwinden. Unsere Vermutung konnte durch eine kombinierte Therapie von 
Canertinib beziehungsweise Pelitinib mit PI3K/AKT Signalweginhibitoren 
bestätigt werden. Diese führte zu einer starken Senkung der Resistenz 
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gegenüber den ErbB Inhibitoren. Des weiteren zeigte diese Therapie besonders 
gute wachstumsinhibierende Effekte in der Kombination von ErbB Inhibitoren 
mit NVP-BEZ 235, einem zweifachen PI3K und mTOR Inhibitor.  
Wir konnten zeigen, dass die Inhibierung des MAPK Signalweges keinen 
wachstumsinhibierenden Effekt hatte, des weiteren ließen unsere Daten 
erkennen, dass eine ErbB unabhängige Aktivierung des PI3K/AKT Signalweges 
ein sehr wichtiger Faktor für die Entwicklung von Resistenz gegenüber den 
ErbB Inhibitoren Pelitinib und Canertinib darstellt. 
 
Table of contents 
 
      
9 
 
Table of contents 
 
Danksagung ........................................................................... 4 
Abstract .................................................................................. 5 
Zusammenfassung ................................................................ 7 
Table of contents ................................................................... 9 
1 Introduction ........................................................................ 13 
1.1 Cancer............................................................................................ 13 
1.1.1 What is cancer ............................................................................................ 13 
1.2 Hallmarks of cancer ....................................................................... 14 
1.2.1 Self-sufficiency in growth signals ............................................................... 15 
1.2.2 Insensitivity to antigrowth signals ............................................................... 16 
1.2.3 Evading apoptosis ...................................................................................... 17 
1.2.4 Limitless replicative potential ...................................................................... 17 
1.2.5 Sustained angiogenesis ............................................................................. 18 
1.2.6 Tissue invasion and metastasis ................................................................. 18 
1.3 Distribution of cancer ..................................................................... 19 
1.3.1 The geographical distribution and incidence rates  
of breast cancer ......................................................................................... 19 
1.4 Risk factors for breast cancer ......................................................... 22 
1.5 Diagnosis of breast cancer ............................................................. 23 
1.6 Treatment strategies in breast cancer ............................................ 23 
1.7 ErbB receptors ............................................................................... 24 
1.7.1 ErbB receptor family ................................................................................... 24 
1.7.2 Ligands of the ERbB receptor family .......................................................... 25 
1.7.3 Downstream signalling of ErbB receptors .................................................. 27 
1.7.4 Trageting of ErbB receptors in cancer ........................................................ 28 
1.7.5 Overexpression of EGFR ........................................................................... 29 
1.7.6 Overexpression of ErbB2 ........................................................................... 30 
1.7.7 Overexpression of ErbB3 ........................................................................... 30 
1.7.8 Overexpression of ErbB4 ........................................................................... 31 
1.8 Downstream signalling pathways of ErbB ...................................... 32 
 
Table of contents 
 
 
10 
 
1.8.1 Mitogen activated protein kinase (MAPK) signalling 
pathway ..................................................................................................... 32 
1.8.2 The phosphatidylinositol 3 kinase (PI3K)/AKT  
signalling pathway ..................................................................................... 33 
1.8.3 Targeting MAPK and PI3K in cancer .......................................................... 35 
2 Material and Methods ......................................................... 37 
2.1 Cell culture and Cell lines ............................................................... 37 
2.1.1 Cell lines ..................................................................................................... 37 
2.1.2 Materials for cell culture .............................................................................. 40 
2.1.3 Cell culture .................................................................................................. 40 
2.1.4 Storage of the cells ..................................................................................... 41 
2.2 Used drugs ..................................................................................... 42 
2.3 Cell proliferation assay (EZ4U) ...................................................... 46 
2.3.1 Background EZ4U ...................................................................................... 46 
2.3.2 Performance of EZ4U assay ...................................................................... 47 
2.4 Protein analysis (Western blotting) ................................................. 48 
2.4.1 Background Western blotting ..................................................................... 48 
2.4.2 Protein extractions ...................................................................................... 50 
2.4.2.1 RIPA Lysis ............................................................................................... 50 
2.4.2.2 Protein Quantification .............................................................................. 51 
2.4.3 SDS-Polyacrylamide Gel Electrophoresis (PAGE) .................................... 53 
2.4.4 Electrotransfer ............................................................................................ 54 
2.4.5 Immunostaining of the Blotted membranes ................................................ 55 
2.4.6 Stripping of the Membranes ....................................................................... 59 
2.5 Statistical analysis .......................................................................... 60 
2.5.1 Analysis of variance (ANOVA) ................................................................... 60 
2.5.2 Scheffé-Test ............................................................................................... 60 
2.5.3 Student’s t-Test .......................................................................................... 61 
3 Results ................................................................................ 62 
3.1 Comparison of pelitinib sensitivity and resistance  
in different breast cancer cell lines ................................................. 62 
3.2 ErbB downstream signalling profiles from a panel  
of breast cancer cell lines exposed to pelitinib ............................... 64 
 
Table of contents 
 
      
11 
 
3.2.1 Investigation of the importance of the MAPK  
pathway in MDA-MB 231 cells .................................................................. 66 
3.3 Determination of the fundamental ErbB downstream 
signalling pathways in SKBR3 and T47D....................................... 67 
3.3.1 Inhibition of the phosphatidylinositol-3-kinase pathway ............................. 67 
3.3.2 Inhibition of the mitogen-activated protein kinase pathway ........................ 70 
3.4 Effects of PI3K pathway inhibitors on AKT, ERK  
and S6 in the two cell lines SKBR3 and T47D ............................... 73 
3.4.1 Influence of mTOR inhibition in the pelitinib sensitive 
         and resistant cell lines ................................................................................ 73 
3.4.2 Dual mTOR and PI3K inhibition in SKBR3 and T47D cell lines ................. 76 
3.4.3 Determination of signalling effects through inhibition of AKT 
         in T47D and SKBR3 cells ........................................................................... 79 
3.5 Effects of MAPK pathway inhibitors on MEK and ERK in  
the two cell lines SKBR3 and T47D ............................................... 81 
3.5.1 Influence of AZD6244 on MAK pathway signalling  
                     in the two pelitinib sensitive and resistant cell lines .................................... 81 
3.5.2 Influence of U0126 on MAPK pathway signalling in 
         the two pelitinib sensitive and resistant cell lines  ...................................... 83 
3.5.3 Influence of AS703026 on MAPK pathway signalling in  
         the two pelitinib sensitive and resistant cell lines  ...................................... 85 
3.6 Overcoming the resistance of T47D against pelitinib ..................... 88 
3.6.1 Combined treatment of SKBR3 and T47D with pelitinib and  
                     PI3K inhibitors ............................................................................................. 88 
3.6.2 Combined treatment of SKBR3 and T47D with canertinib and  
PI3K inhibitors ........................................................................................... 92 
3.6.3 Cotreatment of SKBR3 and T47D cells with pelitinib and 
         MAPK inhibitors .......................................................................................... 96 
3.6.4 Cotreatment of SKBR3 and T47D cells with canertinib and 
         MAPK inhibitors .......................................................................................... 99 
4 Discussion .......................................................................... 103 
4.1 Responsiveness of different breast cancer cell lines to  
ErbB inhibition ................................................................................ 104 
 
Table of contents 
 
 
12 
 
4.2 Fundamental ErbB downstream signalling pathway of  
SKBR3 and T47D .......................................................................... 106 
4.2.1 Examination of the growth inhibitory effects of PI3K  
       and MAPK pathway inhibitors ..................................................................... 106 
4.2.2 Examination of the downstream signalling effects of  
       PI3K and MAPK pathway inhibitors ............................................................ 108 
4.3 Combined therapy in SKBR3 and T47D cell lines .......................... 111 
5 References .......................................................................... 113 
6 Curriculum vitae ................................................................. 124
         Introduction 
 
 
13 
 
1.Introduction 
1.1 Cancer 
1.1.1 What is cancer 
Cancer is characterized as a disease with uncontrolled expansion and invasion 
of cells. These cells display deregulted cell proliferation and suppression of 
apoptosis (Evan et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Mutations in stem cells or progenitor cells might give rise to cancer stem 
cells (Bjerkvig et al., 2005). 
 
 
The progress which leads to a transformation of normal cells to malignancy 
requires mutations which arise as a consequence of damage to the genome.  
Cancer stem cell might appear after mutations in specific stem cells or early 
stem cell progenitors. Moreover it is also possible that cancer stem cells can be 
derived from differentiated cells. There might be numerous factors in the host 
microenvironment that trigger the initial steps of tumor formation (Figure 1).  
Mutational damage can be the result of endogenous processes such as errors 
in replication of DNA, through the intrinsic chemical instability of certain DNA 
bases or from the attack by free radicals generated during metabolism. 
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DNA damage can also be a result from interactions with exogenous agents 
such as ionizing radiation, UV radiation and chemical carcinogens.  
Cells have evolved some mechanisms to repair such damage, but for different 
reasons errors occur and permanent changes in the genome are introduced.  
The evolution of a normal cell to a malignant one, involves processes by which 
genes involved in normal homeostatic mechanisms that control proliferation and 
cell death suffer mutational damage. This can result in the activation of genes, 
which stimulate proliferation or protection against cell death. These genes are 
called oncogenes. In contrast, altered genes that in their wild type-form would 
inhibit proliferation and called tumor suppressor genes. When a cancer cell 
overcomes normal controls on cell brith and cell death, this cell has two 
challenges, it must overcome replicative senescence and become immortal. In 
addition, this cell must obtain adequate supplies of nutrients and oxygen, to 
maintain this high rate of proliferation (Bjerkvig et al., 2005; Bertram et al., 
2000). 
 
1.2 Hallmarks of cancer 
 
There are a lot of different types of cancer and subtypes of tumors found in 
specific organs. In general there are six essential alterations in cell physiology, 
which cause malignant growth (Figure 2). 
         Introduction 
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Figure 2: Hallmarks of cancer, suggestion that most cancers have acquired the same 
set of function capabilities during their development (Hanahan et al.,2000). 
 
These six alterations are self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, tissue invasion and 
metastasis. This multiplicity of defenses may explain why cancer is relatively 
rare during an average human lifetime (Hanahan et al.,2000).  
 
1.2.1 Self-sufficiency in growth signals 
 
Normal cells require mitogenic growth signals, before they can move to an 
active proliferative state. These signals are transmitted into the cell by 
transmembrane receptors that bind specific signalling molecules. No normal 
type of cell is able to proliferate in the absence of such stimulatory signals. 
However tumor cells show a strongly reduced dependence on exogenous 
growth stimulation. A possible reason could be that they generate many of their 
own growth signals and thereby reducing their dependence on stimulation from 
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their normal tissue microenvironment. This mechanism disrupts a critically 
important homeostatic function that normally ensures a proper behavior of 
different cell types. To stimulate tumor cell growth, cancer cells possess 
uncontrolled overexpression or activation of cell surface receptors, which 
transduce stimulating signals into the cell. For example the epidermal growth 
factor receptor EGFR/ErbB1 or more frequently (~20%), or the 
HER2/neu/ErbB2 receptor is overexpressed in mammary carcinomas  
(Hanahan et al., 2000).    
 
1.2.2 Insensitivity to antigrowth signals 
 
Normal tissues have mutiple antiproliferative signals to maintain cellular 
quiescence and tissue homeostasis. These signals include soluble growth 
inhibitors and immobilized inhibitors embedded in the extracellular matrix and 
on the surfaces of nearby cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Phases of the cell cycle (1). 
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Antigrowth signals can block proliferation by two distinct mechanisms. Cells can 
be forced out of the active proliferative cycle into the quiescent (G0) state from 
which they may reemerge on some future occasion when extracellular signals 
permit (Figure 3). Second mechanism is that cells may be induced to 
permanently relinquish their proliferative potential by being induced to enter into 
postmitotic states, which are normally associated with the acquisition of specific 
differentiation traits. Cancer cells have to avoid these antigrowth signals, for an 
unlimited proliferation. 
Therefore often mutations are found in components which are responsible for 
the regulation of proliferation. For example retinoblastoma protein (pRb), which 
controls the expression of different genes, is important for the cell cycle 
progression from G1 to S phase (Hanahan et al., 2000).   
 
1.2.3 Evading apoptosis 
 
The ability of tumor cells to expand is determined by the rate of cell proliferation 
and also by the rate of cell death. A resistance against apoptosis is a hallmark 
of most and maybe all types of cancer. To circumvent apoptosis tumor cells 
intervene antiapoptotic survivalsignals and regulate tumor suppressors.  
Oncogenes which are expressed in a high level help to turn normal cells into 
cancer cells. Such genes for example RAS and c-Myc as well as tumor 
suppressors like p53 and PTEN are an important part of this alteration 
(Hanahan et al., 2000). 
 
1.2.4 Limitless replicative potential 
 
Furthermore cancer cells require unlimited replicative potential. For this feature 
telomere play an essential role. Telomeres are the end of chromosomes and 
consist of several thousand repeating sequences and have a protective 
function. Telomere maintenance is evident in all types of malignant cells.  
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Therefore, they upregulate the expression of telomerase enzyme, which adds 
hexanucleotide repeats onto the ends of telomeric DNA or they use a rare 
mechanism called alternative lengthening of telomeres (ALT). In both 
mechanisms telomeres are maintained at a length above a critical threshold and 
this in turn permits unlimited multiplication of descendant cells.  
These two mechanisms seem to be strongly suppressed in most normal human 
cells, to deny them unlimited replicative potential (Hanahan et al., 2000).   
 
1.2.5 Sustained angiogenesis 
 
The oxygen and nutrients supplied by the vasculature are crucial for cell 
function and survival. Therefore, it is necessary that all cells in a tissue are 
provided with a capilary blood vessel. When a tissue is formed, the growth of 
new blood vessels, this process which is called angiogenesis is very carefully 
regulated. Tumor cells, which rapidly divide, often lack angiogenic ability. So 
they have to develop angiogenic ability to get a good supply with nutrients, 
which is necessary for growth. Counterbalancing positive and negative signals 
encourage or block angiogenesis. These signals are for example vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Moreover 
integrins and adhesion molecules, which mediate cell-matrix and cell-cell 
association, also play critical roles. Tumors activate the angiogenic switch by 
changing the balance between angiogenesis inducers and countervailing 
inhibitors. One common strategy for shifting the balance involves altered gene 
transcription (Hanahan et al., 2000). 
 
1.2.6 Tissue invasion and metastasis 
 
The capability for invasion and metastasis enable cancer cells to escape the 
primary tumor mass and colonize new terrain in the body where no limiting of 
nutrients and space is present. Such distant settlements of tumor cells and  
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metastases are the cause of 90% of human cancer deaths. Invasion and 
metastasis are complex processes, which involves changes in the physical 
coupling of cells to their microenvironment and activation of extracellular 
proteases. Several different proteins which are involved in the tethering process 
of cells to their surroundings in tissue are altered. These proteins include cell-
cell adhesion molecules (CAM). The most observed alteration in cell to 
environment interactions in cancer involves E-cadherin, a homotypic cell to cell 
interaction molecule, which is ubiquitously expressed on epithelial cells. A 
coupling between adjacent cells by E-cadherin bridges results in the 
transmission of antigrowth and other signals, via cytoplasmic contacts with β-
catenin to intracellular signalling circuits.  
The second parameter of the invasive and metastatic capability involves 
extracellular proteases. Docking of active proteases on the cell surface can 
facilitate invasion by cancer cells into nearby stroma, across blood vessels walls 
and through normal epithelial cell layers (Hanahan et al., 2000).  
 
1.3 Distribution of cancer 
 
1.3.1 The geographical distribution and incidence rates of breast cancer  
 
Breast cancer is the most common malignancy in women worldwide and is the 
leading cause of cancer related mortality. 45% of the more than one million new 
cases of breast cancer diagnosed each year, and more than 55% of breast-
cancer–related deaths, occur in low- and middle income countries. There is a 
higher prevalence of breast cancer in industrialised than in non industrialised 
countries.  
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Figure 4: Incidence and mortalitiy rate of breast cancer in the world 
(Porter et al., 2008). 
 
East Asian women still have the lowest rates of breast cancer (Figure 4). Japan, 
Singapore and Korea, countries with the most developed registries, 
documented increasing rates. They have doubled or tripled in the past 40 years. 
In India there are similar trends observed, with increased concentrations in 
urban areas.  
The incidence of breast cancer in African countries is lower than overall rates in 
North America or Western Europe, as well as lower than rates among black 
women living in these Western countries.  
The most reason for the global increase in breast cancer is the socioeconomic 
improvement that increase life expectancy and allow women reproductive  
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control as well as the adoption of less desirable habits. This is called 
Westernization and can strongly contribute to an increase in breast cancer risk 
(Porter et al., 2008). Breast cancer is a postmenopausal disease, with more 
than three-quarters of tumors hormone responsive. 
This hormone dependency interacts with environmental and genetic factors to 
determine incidence and progression of the disease. Age and female sex are 
major risk factors for breast cancer, with rapidly rising incidence rates, between 
the age of 35 and 39 years. The age of increase slows around the age of 50 
years, corresponding to the average age of menopause. Figure 5 shows two 
separate rate curves for oestrogen receptor positive and negative tumors. The 
incidence of oestrogen receptor negative tumors increases rapidly until age 50 
years and then flattens or 
decreases. But the 
incidence of oestrogen 
receptor positive tumors is 
similar up to the age of 50 
years, but then continues 
to climb at a slower pace.  
Oestrogen receptor 
negative tumors occur 
earlier in life and oestrogen 
receptor positive tumors 
are more common in older 
women (Benson et al., 
2009). 
 
 
 
Figure 5: Age specific incidence rates in female  
patients suffer on breast cancer (Benson et al., 2009). 
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1.4 Risk factors for breast cancer 
 
One of the strongest risk factors for breast cancer is increasing age. Early age 
at menarche, late age at menopause, nulliparty and late age at first birth 
increase the risk for breast cancer. But breastfeeding is associated with lower 
risk. Obesity in Western countries is associated with breast cancer 
development. Moreover, there are some gene mutations identified, which also 
contribute to breast cancer. These mutations are tumor suppressor genes, for 
example BRAC1, BRAC2 and PTEN (Hankinson et al., 2004).  
A germ line mutation in the BRCA1 or BRCA2 gene is the most detectable 
cause of a heritable risk of breast cancer. 40-50% of families with multiple 
cases of female breast cancer are linked to these genes (Robson et al., 2007).  
An association between alcohol consumption and breast cancer was observed 
in epidemiologic studies. Alcohol affects plasma oestrogenes, which also have 
an influence of breast cancer risk. Alcohol consumption is positively associated 
with ER positive and PR positive breast cancers, but not with ER negative and 
PR negative cancers. This leads to the suggestion that alcohol may act in part 
through the estrogen pathway, to affect breast cancer risk. It may also affect 
breast cancer risk by acting as a co carcinogen. Alcohol increases the 
permeability of cell membranes to carcinogenes, being mutagenic through 
acetaldehyde, inhibiting detoxification of carcinogenes, activation of 
procarcinogenes, inducing oxidative stress and affecting folate metabolism 
(Zhang et al., 2007). Moreover it was found, that oestrogen and progesterone 
play a very important role in breast cancer development. Studies revealed that 
hormone replacement therapy (HAT) leads to an increased risk of breast cancer 
in healthy women (Holmberg et al., 2008).  
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1.5 Diagnosis of breast cancer 
 
Patients with breast cancer have to be scanned precisely. Different factors have 
to be evaluated clinically. A mammographic screening leads to the detection of 
malignancy. Moreover, screening mammography in postmenopausal women 
reduces breast cancer mortality by about 20%. Complementary to 
mammography, breast ultrasound is made, it increases diagnostic accuracy. 
Tissue diagnosis is also essential and can be obtained with fine needle 
aspiration cytology. Percutaneous needle biopsy techniques can now provide a 
definitive diagnosis for benign and malignant diseases. To clarify the extent of a 
lesion and to establish, whether satellite foci are present in patients, magnet 
resonance imaging (MRI) is used (Benson et al., 2009).  
 
1.6 Treatment strategies in breast cancer 
 
The primary treatment of localized breast cancer is either breast conserving 
surgery and radiation therapy or mastectomy with or without breast 
reconstruction. Systemic adjuvant therapies, which eradicate microscopic 
deposits of cancer cells that may have spread or metastasized from the primary 
breast cancer, show an increasing chance for long term survival in breast 
cancer patients. Such systemic adjuvant therapies include chemotherapy, with 
anticancer drugs and hormone therapy.                                                     
In addition radiotherapy in some cases as a local adjuvant treatment to destroy 
breast cancer cells, which remain in the chest wall or in regional lymph nodes 
after mastectomy. Breast cancer must be determined precisely in tumor size, 
histological type, age of the patient and biomarkers like estrogen receptor status 
and progesterone receptor status, to find the best treatment option for breast 
cancer patients (Eifel et al., 2001).  Breast conservation surgery is a procedure, 
which is preferred for women with early stage breast cancer. Moreover 
widespread mammographic screening has contributed to a stage shift for newly  
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diagnosed disease, with an average tumour size of less than 2cm. Interestingly, 
long term follow up of breast conservation trials show increased rates of local 
relapse when radiotherapy is omitted. Therefore breast conservation surgery is 
combined with whole breast irradiation. With new partial breast irradiation 
techniques called intraoperative radiotherapy and MammoSite intraoperative 
radiotherapy, high dose of radiation can be applicated as one fraction at the 
time of surgery. This technique allows a precise application of radiation to the 
targeted area, to eliminate tumor foci around the surgical bed (Benson et al., 
2009). 
 
1.7 ErbB receptors 
 
1.7.1 ErbB receptor family   
 
The ErbB receptor family plays a very important role in the pathogenesis of 
breast cancer (Karamouzis et al., 2006). Moreover, when epidermal growth 
factor-like ligands bind to the ErbB family receptors, a network of signalling 
pathways is activated, which influence cell division, apoptosis, motility and 
adhesion (Yarden et al., 2006). The ErbB receptor family consists of four 
different types of receptors. EGFR/ErbB1/Her1, ErbB2/Her2/neu, ErbB3/Her3 
and ErbB4/Her4. All these receptors have intrinsic tyrosine kinase activity 
except Her3. Her2 does not bind any ligand, but it is a preferred partner for 
heterodimerisation. Because Her2-containing heterodimers show higher 
membrane stability and decreased degradation rates than heterodimers 
containing other partners, they are more mitogenic than others. In particular, the 
Her2/Her3 heterodimer is the most potent growth-stimulating ErbB signaling 
complex (Karamouzis et al., 2006).  
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1.7.2 Ligands of the ErbB receptor familiy 
 
ErbB receptors are activated by a number of ligands that constitute the EGF 
family of peptide growth factors. These peptides are produced as membrane-
anchored precursors and are processed and released by proteolysis.  
There exist a large number of ErbB specific ligands (Figure 6), and all of them 
contain an EGF like domain, which is sufficient for binding specificity.  
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6: Binding specficities of the EGF 
related peptide growth factors (Olayloye et al., 2000). 
 
These ligands included EGF, amphiregulin (AR), and transforming growth 
factor-α (TGFα), which bind specifically to ErbB1. Moreover, there are 
betacellulin (BTC), heparin binding EGF (HB-EGF) and epiregulin (EPR). EPR 
exhibits dual specificity, it binds both ErbB1 and ErbB4. Neuregulins (NRG) 
comprise the third ligand family.  
NRG-1 and NRG-2 bind to ErbB3 and ErbB4 whereas NRG-3 and NRG-4 only 
bind to ErbB4 but not to ErbB3. The binding of ligands to these receptors leads 
to the formation of homo- and heterodimers. This stimulates the intrinsic  
Introduction 
 
 
26 
 
intracellular tyrosine kinase activity of the receptors and triggers 
autophosphorylation of specific tyrosine residues in the cytoplasmic of the 
receptor protein domain. These phosphorylated residues serve as docking sites 
for signalling molecules, which are involved in the regulation of intracellular 
signalling cascades.  
For ErbB2 no direct ligand has been discovered so far. Therefore, the 
suggestion is that its primary function is as a coreceptor. Moreover, ErbB2 is the 
most preferred heterodimerization partner (Figure 7) for all other ErbB familiy 
members (Olayloye et al., 2000). 
 
 
Figure 7: ErbB2 serves as a preferred dimerization partner for the other ErbB 
receptors (Olayloye et al., 2000). 
 
 
Furthermore ErbB3 homodimers are not able to signal, because ErbB3 
harbours a catalytically deficient kinase domain. Therefore, ErbB3 signalling 
relies on the formation of signalling competent heterodimers with other ErbB 
family members (Karamouzis et al., 2006). ErbB2 and ErbB3 heterodimers are 
the most potent ErbB signalling complexes. In cancer EGFR and ErbB2 are 
often overexpressed and are associated with a poor clinical prognosis (Olayloye 
et al., 2000). 
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1.7.3 Downstream signalling of ErbB receptors 
 
Regulation of the intracellular signalling pathways, which become activated by 
ErbB receptors is very complex. The ligand-receptor composition on a cell, the 
availability of intracellular docking molecules and, moreover, negative effectors, 
which downregulate the signal are some key parameters that determine the 
final outcome of ErbB activation.  
The binding of ligand influences, which tyrosines on a particular ErbB protein 
become phosphorylated, which in turn determines what type of signalling 
molecules is to be enrolled in the downstream events. Binding of cytoplasmic 
mediators, including adaptor proteins or enzymes, occur through their Src-
homology 2 (SH2) - or phosphotyrosin-binding (PTB)-domains, whereas the 
recruitment specificity is determined by the amino acids surrounding the 
autophosphorylation site on the receptor itself. The Shc- or Grb2- activated 
mitogen–activated protein kinase (MAPK) pathway is a common downstream 
target of many receptors. In the same way, the phosphatidylinositol-3-kinase 
(PI3K) pathway becomes activated by most ErbBs. However, the signalling 
extent depends upon the receptor, because for example ErbB3 couples 
particularly well to this pathway because of its multiple p85 (subunit of PI3K 
pathway) docking sites, whereas ErbB4 directly recruits p85. There are other 
cytoplasmic docking proteins, which are reruited by specific ErbB receptors and 
less exploited by others. These include for example the GTPase activation 
proteins (GAP), the protein tyrosine phosphatise SHP-1 and the intracellular 
tyrosine kinase Src. Moreover, the duration of signalling is another key factor in 
the defining of the biological output. The stimulation of cytoplasmic pathways 
transduces the signal to the nucleus, where a lot of transcription factors 
undergo activity changes, this leads to the initiation of many transcription 
programs. There are numerous transcription factors downstream of ErbBs, 
which have been described. They include c-Jun, c-Fos and c-Myc, NF-κB, zinc-
finger transcription factors and signal transducer and activator of transcription  
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(Stat). Therefore, the ErbB signalling network controls a wide array of biological 
outcomes, including cell proliferation, differentiation, survival, adhesion and 
migration (Holbro et al., 2004). 
 
1.7.4 Targeting of ErbB receptors in cancer 
 
ErbB receptors, 
especially EGFR 
and ErbB2 play a 
very important 
role in the 
development and 
malignancy of 
human cancer 
(Olayloye et al., 
2000). 
 
Figure 8: Different targeting strategies of ErbB receptors in cancer  
cells (Citri et al., 2006).    
 
For treatment, monoclonal antibodies, tyrosine kinase inhibitors, heat shock 
protein- 90 (HSP90) inhibitors and drug combination are used.  
Monoclonal antibodies act by recruiting cytotoxic lymphocytes. Moreover, they 
have direct effects on signalling in the target tumor cell itself. Antibodies, which 
are nowadays in use, are trastuzumab, which targets ErbB2 and Cetuximab, 
which targets ErbB1 (Figure 8) Tyrosine kinase inhibitors are small molecules 
which act by blocking the nucleotide binding site of ErbB receptors. Two ErbB1 
inhibitors, erlotinib and gefitinib, are in use for the treatment of non small lung 
cancer. But a much more effective strategy is the use of dual inhibitors like 
lapatinib, which targets both ErbB1 and ErbB2. ErbB2 strongly depends on the  
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HSP90 chaperone complex to maintain its stability. This could therefore be a 
good possibility to target ErbB2. Therefore, the clinical efficacy of HSP90 
inhibitors like 17-N-allylamino-17-demethoxygeldanamycin are under 
evaluation. However, cellular dynamics and genetic heterogeneity underlie 
tumor resistance to these drugs. Therefore, combination treatment strategies 
are being developed, that aim to prevent tumor recurrence. Combination of anti-
ErbB drugs with anti cancer chemotherapy and radiotherapy appears to be a 
promising way to overcome drug resistance (Citri et al., 2006).  
 
1.7.5 Overexpression of EGFR 
 
Overexpression of EGFR is associated with malignancy and with enhanced 
ability of certain tumors to invade normal tissues and to metastasize (Korc et al., 
1992). EGFR is overexpressed in a variety of human cancers. This 
overexpression is correlated with a loss of estrogen responsiveness and poorer 
prognosis. EGFR is involved in later stages of human breast cancer and may 
play an important role in the metastatic process (Biscardi et al., 2000).  
By the use of EGFR-targeting small-molecule tyrosine kinase inhibitor gefitinib 
(ZD1839, Iressa), the growth of cell lines that express high levels of EGFR 
could be inhibited. ZD1839 promotes the formation of inactive EGFR/ErbB2 and 
EGFR/ErbB3 heterodimers (Anido et al., 2003). Moreover, gefitinib, which is a 
quinazoline tyrosine kinase inhibitor, shows good growth inhibitory effects in 
EGFR and Her2 overexpressing breast cancer, which was associated with the 
dephosphorylation of EGFR and Her2 and a down-regulation of Akt activity 
(Moasser et al., 2001). Erlotinib is another EGFR receptor tyrosine kinase 
inhibitor. It inactivates EGFR downstream signalling (Schaefer et al., 2007).  
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1.7.6 Overexpression of ErbB2 
 
Ligand-independent activation and prolonged membrane stability of 
overexpressed ErbB2 in combination with its preferred role as a dimerization 
partner is responsible for its high oncogenic potential. Moreover, the level of 
ErbB2 in human cancer cells with membrane overexpression is much higher 
than in normal adult tissues. Therefore, ErbB2 is a good target for cancer 
therapy. A monoclonal antibody (clone 4D5) targets the extracellular domain of 
ErbB2. The humainized version of this antibody (trastuzumab, herceptin) is 
used to treat ErbB2-positive metastatic breast cancer. This treatment results in 
a rapid reduction of ErbB2 phosphorylation. But not all ErbB2 overexpressing 
cells show downstream effects to Herceptin treatment. Phase II and III trials in 
metastatic disease showed that trastuzumab has relevant clinical activity 
against ErbB2 positive breast cancer (Valabrega et al., 2007; Olayioye et al., 
2000). But lots of patients, who originally responded to trastuzumab therapy, 
become resistant within one year of treatment. Trastzuzmab inhibits ErbB2, 
therefore EGFR/ErbB3 heterodimers are formed, which signal through the 
MAPK and PI3K/AKT signalling pathway. Hence, breast cancer cells become 
resistant against trastuzumab. Therefore, combination of different inhibitors 
could be a good therapeutic strategy (Natha et al., 2006).   
ErbB2 overexpression stimulates the MAPK and PI3K/AKT pathway and 
therefore promotes cell cycle progression. The combination of ErbB2 
overexpression and activation of ErbB downstream signalling pathways often 
leads to multidrug resistance in breast cancer cell lines (Knuefermann et al., 
2003).  
 
1.7.7 Overexpression of ErbB3 
 
In the ErbB family ErbB3 is inimitable, because of its catalytically deficient 
kinase domain and the high propensity to self associate in the absence of  
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ligand. The ErbB3 gene is located on chromosome 12q13. Its signalling relies 
on the formation of heterodimers with other ErbB members. ErbB3 is 
overexpressed in many cancers, like breast, lung, pancreas and stomach. 
Furthermore, this overexpression is documented in 20-30% of invasive and in 
approximately one third of in situ breast carcinomas. Moreover, its 
overexpression in cancer is associated with poor prognostic factors. The most 
mitogenic dimerization partners of ErbB receptors are ErbB2/ErbB3 
heterodimers. They are constitutively active in breast cancer cells with ErbB2 
overexpression. Drug resistance in a lot of ErbB2 overexpressing cancers rely 
on an increasing level of ErbB3 and/or EGFR. The EGFR/ErbB3 heterodimer 
signals through RAS-MAPK signalling pathway. PI3K activation in response to 
the binding of ligands is mostly mediated by ErbB3, because this receptor has 
multiple binding sites for the p85 regulatory subunit of the PI3K (Karamouzis et 
al., 2006).    
 
1.7.8 Overexpression of ErbB4 
 
The ErbB4 gene is located on chromosome 2q33.3-34 and encodes a 
transmembrane glycoprotein, which is very important in the development and 
differentiation of various tissues, especially the cardiovascular, the neural 
system and mammary glands, as well as in different pathological processes, 
including malignancy. However, ErbB4 is not frequently overexpressed in breast 
carcinomas, compared to other ErbB members. Its overexpression is 
associated with increased estrogen receptor and cell proliferation rates. Cell line 
experiments show that ErbB2 positive cancer cells transfected to overexpress 
ErbB4 lead to a reduction in proliferation and an increase in apoptosis 
(Karamouzis et al., 2006). Therefore, ErbB4 expression can serve as a marker 
of survival in breast cancer. Moreover, it was described that ErbB4 
overexpression can be associated with cell growth and cell progression, which 
leads to the suggestion that there are differences in breast cancer subtypes,  
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according to ER+ and ER- tumors. Furthermore, breast cancer overexpressing 
ErbB4 in ER+ tumors have a good prognosis (Sundvall et al., 2008). Mutations 
of ErbB4 have been found in many cancers including breast cancer. Mutated 
ErbB4 is most frequently seen in melanoma, where it appears to be the only 
ErbB receptor which is altered by mutation. Moreover, mutant ErbB4 is one of 
the driving forces for the development of melanoma. It should therefore be 
targeted by novel pan-ErbB inhibitors (Rudloff et al., 2010). 
 
1.8 Downstream signalling pathways of ErbB 
 
1.8.1 Mitogen activated protein kinase (MAPK) signalling pathway 
 
The phosphorylation by the receptor tyrosine kinase of specific tyrosine 
residues on Shc and IRS-1 generates binding sites, which are necessary for the 
recruitment of the Grb2/Sos complex to the plasma membrane, where Sos 
mediates Ras activation by stimulating Ras to exchange GDP for GTP (Figure 
9). The activation of Ras leads to the recruitment of Raf, a MAP kinase kinase 
kinase, to the membrane. There it is subsequently activated. Raf 
phosphorylates a MEK which phosphorylates the MAP kinases (ERK1 and 
ERK2) on critical tyrosine and threonine residues. The activation of MAP kinase 
leads to the phosphorylation of both cytoplasmic and nuclear targets, including 
the ribosomal subunit protein kinase p90RSK and transcription factors Elk-1, 
cMyc, c-Jun and c-Fos, which are all important in mediating cell cycle 
progression and proliferation. Moreover, the Ras/MAP kinase pathway is 
involved in the regulation of cell differentiation and cell survival signalling 
(Hermanto et al., 2000).  
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Figure 9: The mitogen activated protein kinase signalling (MAPK) pathway (2). 
 
 
1.8.2 The phosphatidylinositol 3 kinase (PI3K)/AKT signalling pathway 
 
After activation of the ErbB receptor family, the PI3K signalling pathway 
activates the protein kinase Akt and therefore promotes proliferation, growth, 
glycogen synthesis, and nitric oxide synthesis is associated with tumorigenesis. 
The initial activation of the phosphatidylinositol 3 kinase pathway occurs at the 
cell membrane (Figure 10), where the signal for pathway activation is 
propagated through PI3K. Activation of PI3K can occur through tyrosine kinase 
growth factor receptors like ErbB family receptors. When PI3K is activated, the 
p85 regulatory subunit of the PI3K binds to the phosphorylated tyrosine 
residues and recruits the second catalytic subunit p110 of the PI3K. After this 
activation, PI3K transforms phosphatidylinositol 4,5 bisphosphate [PI(4,5)P2] 
also called PIP2 into phosphatidylinositol 3,4,5 triphosphate [PI(3,4,5)P3] also 
called PIP3. Thereafter, PI(3,4,5)P3 binds to the pleckstrin homology (PH) 
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domains of the 3’-phosphoinositide dependent kinase 1 (PDK-1) and the 
serine/threonine kinase Akt, which cause both proteins to be translocated to the 
cell membrane, where they are subsequently activated. PTEN (phosphatide and 
tensin homolog on chromosome ten)-a tumor suppressor- antagonizes PI3K by 
dephosphorylating PI(3,4,5)P3, to prevent translocation and activation of Akt 
and PDK-1. Akt is available in three structurally similar isoforms, Akt1, 2 and 3. 
The activation of Akt1 at the cell membrane occurs through two crucial 
phosphorylations. First, phosphorylation takes place at Thr308 in the catalytic 
domain, by PDK-1. The second one occurs at Ser473, in the hydrophobic motif, 
mediated by different kinases for example PDK-1, integrin linked kinase, Akt 
itself or mammalian target of rapamycin (mTOR). Phosphorylation of Akt2 and 3 
takes place by the same mechanism (Testa et al., 2001; Nicholson et al., 2002; 
LoPiccolo et al., 2007). Moreover, the PI3K/AKT pathway is very important for 
normal cellular homeostasis and cancer growth, because it has a central role as 
a cross-over point between growth, differentiation, apoptotic pathways and 
metabolic systems like tumorigenic lipogenesis (Grunt et al., 2009).  
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Figure 10: The phosphatidylinositol 3 kinase (PI3K)/AKT signalling pathway (3). 
 
 
1.8.3 Targeting MAPK and PI3K in cancer 
 
The protein kinase MEK occupies a crucial signalling node downstream of RAS 
and RAF and directly upstream of ERK. Analyses of MEK function shows, that it 
is necessary for the transforming and proliferative effects of the MAPK pathway. 
Therefore, the suggestion was to block its function with specific enzyme 
inhibitors such as with PD0325901 and AZD6244. These molecules act through 
a noncompetitive allosteric mechanism of inhibition, by the binding to a site 
adjacent to the ATP-binding site and locking the kinase in a closed and 
catalytically inactive conformation. Furthermore, the phosphatidylinositol 3 
kinase (PI3K) pathway, which signals through AKT represents a key 
mechanism of transducing prolifertive and antiapoptotic signals. Activating 
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mutations in the catalytic subunit of p-110α (PIK3CA) occur in 25-30% of breast 
tumors. Moreover, inactivation of the tumor suppressor protein PTEN, which 
acts as an upstream inhibitor of PI3K, has been observed in a significant 
proportion of breast cancer patients. Treatment of breast cancer cell lines with a 
MEK inhibitor can lead to a feedback upregulation of the PI3K signalling 
pathway (Figure 11). 
 
 
Figure 11: Different treatment strategies of receptor tyrosine kinases (Rexer et al., 
2009). 
 
 
Moreover the inhibition of pathways downstream of PI3K results in an 
upregulation of MEK. Therefore, in many cancer cells, in which PI3K and MEK 
are hyper active, the combined inhibition is necessary to affect tumor cell 
survival (Hoeflich et al., 2009; Rexer et al., 2009). 
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2 Material and Methods 
2.1 Cell culture and cell lines 
2.1.1 Cell lines 
Table 1: Overview of the used cell lines, their growth medium, specification and source 
(Hoeflich et al., 2009). 
  Cell line                   Growth medium                Specification                      Source 
T47D                            D-MEM                      H1047R PIK3CA mutation,               ATCC 
                                                                   PTEN WT, low pAkt(S473) level 
SKBR3                         D-MEM                      EGFR protein expression,                ATCC 
                                                              PTEN WT, moderate pAkt(S473) level 
MCF7                           D-MEM                      EGFR protein expression,                ATCC 
                                                                E545K PIK3CA mutation, PTEN WT, 
                                                                          low pAkt(S473) level 
BT474                          α-MEM                      K111N PIK3CA mutation,                 ATCC 
                                                              PTEN WT, moderate pAkt(S473) level 
MDA-MB 231               α-MEM                     EGFR protein expression,                 ATCC 
                                                                     KRAS mutation, PTEN WT, 
                                                                          low pAkt(S473) level 
 
T47D   
The T47D ductal carcinoma cell line 
(Figure 12) was isolated from a human 
mammary tumor. T47D was cultivated in 
D-MEM with 10% heat inactivated fetal 
calf serum (FCS-HI) and 100 U/ml 
penicillin, 100 µg/ml streptomycin and 
2mM L-glutamine (PSG). The cells were 
passaged once a week, at a splitting ratio 
of 1:12. 
 
 
Figure 12: Morphology of T47D cell line (4). 
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SKBR3 
The adenocarcinoma cell line SKBR3 
(Figure 13) was islolated from a human 
mammary tumor. 
This cell line was maintained in D-MEM 
supplemented with 10% FCS-HI and 
PSG. The cells were subcultured once a 
week, at a ratio of 1:8. 
 
 
Figure 13: Morphology of SKBR3 cell line (5). 
 
 
 
MCF7       
This adenocarcinoma cell line (Figure 14) 
descends from a human mammary tumor. 
The MCF7 cell line was cultivated in D-
MEM with 10% FCS-HI and PSG. 
The cells were passaged once a week, at 
a splitting ratio of 1:12. 
 
 
Figure 14: Morphology of MCF7 cell line (6). 
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BT474  
The BT474 ductal carcinoma cell line 
(Figure 15) was isolated from a human 
mammary tumor. 
This cell line was maintained in α-MEM 
with 10% FCS-HI and PSG. BT474 cell 
line was subcultured once a week, at a 
ratio of 1:3. 
 
 
 
 
Figure 15: Morphology of BT474 cell line (7). 
 
 
 
MDA-MB 231     
The MDA-MB 231 adenocarcinoma cell 
line (Figure 16) descends from a human 
mammary tumor.  
This cell line was cultivated in α-MEM with 
10% FCS-HI and PSG. MDA-MB 231 
cells were subcultured once a week, at a 
splitting ratio of 1:12. 
 
 
 
 
Figure 16: Morphology of MDA-MB 231 cell line (8). 
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2.1.2 Materials for cell culture 
 
Table 2: List of used materials for cell culture and their source. 
  Material                                                                                                 Source 
 T25 tissue culture flasks 50ml/25cm2                                                                        Falcon 35/3108 
 T75 tissue culture flasks 250ml/75cm2                                            Falcon 35/3111 
 60x15mm tissue culture dishes                                                       Corning 8430166 
 96-well plates with flat bottom                                                         TPP 92696 
 Cryotubes                                                                                        NUNC 368632 
Alpha MEM w/nucleosides                                                               GIBCO 22571-020 
D-MEM high glucose 4500mg/l                                                        GIBCO 41965-039 
Penicillin/Streptomycin                                                                     GIBCO 15140-148 
L-Glutamin 200mM                                                                           GIBCO 25030-032 
Fetal calf serum (FCS)                                                                     GIBCO 10270-106 
Trypsin-EDTA 0,05%                                                                       GIBCO 25300-054 
Dulbecco’s sulphate buffered saline (D-PBS)                                  GIBCO 14190 
Dimethyl-sulfoxide DMSO                                                                Sigma D2650 
 
 
2.1.3 Cell culture 
 
All cell lines (Figure 12 –16) were maintained at 37°C in 5 % CO2 atmosphere 
with 95 % humidity. They were cultured in two T25 tissue culture flasks per cell 
line, in 7ml medium containing 10% Fetal calf serum (FCS) with 100U/ml 
Penicillin, 100μg/ml Streptomycin and 2mM L-Glutamine (PSG). The cells were 
passaged at a confluence of approximately 90-95%. For the passage, the 
culture medium was removed. Then the cells were washed carefully with D-PBS 
and incubated with Trypsin-EDTA for 5 minutes at 37°C to detach them. These 
cells were resuspended with respective medium to obtain a single cell 
suspension and plated into two new T25 culture tissue flasks at a splitting ratio 
of 1:3 to 1:12. The cell lines were passaged once a week and the confluence 
was controlled with a light microscope. 
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2.1.4 Storage of the cells 
 
The cells were only used until passage 30 for the experiments, to prevent 
mutations or other long term effects. For that reason cells were expanded and 
stored (at a density of  2x106 cells/ml) in liquid nitrogen. To freeze the cells, they 
were washed carefully with PBS and incubated with Trypsin-EDTA for 5 
minutes at 37°C to detach them. Then the cells were resuspended in 10ml 
respective culture medium with 10% FCS and PSG and centrifuged at 1000rpm 
for 5 minutes. The cell pellet was again resuspended in 2ml culture medium 
with 15% FCS and PSG. Then the cells were counted in a counting chamber 
under the light microscope. After the counting, the cell suspension was adjusted 
to 4x106 cells/ml with culture medium containing 15% FCS and PSG. Then this 
suspension is diluted 1:2 with culture medium containing 20% DMSO, so the 
final DMSO concentration is 10%. Before the cells were frozen in liquid 
nitrogen, they were slowly frozen in cryotubes. First in an isolated styrofoam 
box at -80°C for 48 hours and then the cells were stored in liquid nitrogen.  
For experiments, cells were thawed from liquid nitrogen. The cryotube with cells 
was transferred from liquid nitrogen to ice, and then to lukewarm water.  
Subsequently, the cell suspension was transferred into a 50ml falcon tube, 
which contained 20ml precooled culture medium (respective for the cell line) 
and centrifuged at 1000rpm for 5 minutes at 4°C. 
The cell pellet was resuspended in 14 ml culture medium and seeded into two 
T25 culture tissue flasks, 7ml each. The cells were cultured for 3 passages 
before they were used in experiments. 
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2.2 Used drugs 
 
Pelitinib: 
 
Figure 17: Molecular structure of pelitinib (Wissner et al., 2008). 
 
Pelitinib or EKB-569 (Figure 17) provided from Wyeth (22 88 32-2) is an 
irreversible tyrosine kinase inhibitor. It was dissolved under sterile conditions in 
DMSO and stored at -80°C. 
This inhibitor targets the epidermal growth factor (EGF or ErbB1, Her1) and the 
epidermal growth factor receptor 2 (EGFR2/Her2 or ErbB-2). It is a 4-anilino-3-
cyano quinoline derivate. This drug inhibits the function of the target enzymes 
by forming a covalent interaction with a conserved cysteine residue, which is 
located in the kinase domain of these proteins. Pelitinib is also used in clinical 
trials to treat colon and lung cancer (Wissner et al., 2008). 
 
 
Canertinib: 
 
 
 
 
 
 
Figure 18: Molecular structure of Canertinib (Arora et al., 2005). 
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Canertinib or CI1033 (Figure 18) provided from Pfizer (0183 805-00028) is an 
irreversible pan-reactive ErbB inhibitor. This drug was dissolved under sterile 
conditions in DMSO and stored at -80°C. 
Canertinib produces rapid irreversible inhibition of all members of the EGFR 
family. It inhibits EGFR kinase activity and has antitumor activity in EGFR-and 
ErbB2-dependent preclinical models. It is also active against ErbB4, but has no 
effect on other tyrosine kinases (Arora et al., 2005).  
 
Rapamycin: 
 
   Figure 19: Molecular structure of Rapamycin (9). 
 
 
Rapamycin (Calbiochem; 553210; Figure 19) inhibits the serine-threonine 
kinase mammalian target of rapamycin (mTOR). The inhibition of the mTOR 
kinase leads to dephosphorylation of its two major downstream signaling 
components, p70 S6 kinase (S6K1) and 4E-BP1 (Mondesire et al., 2004). 
Rapamycin was dissolved in DMSO under sterile conditions and stored at -
80°C. 
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Akti-1,2: 
 
Figure 20: Molecular structure of Akti-1,2 (10). 
 
  
Akti-1, 2 (Akt Inhibitor VIII; Calbiochem; 124018; Figure 20) is a reversible 
quinoxaline compound that selectively inhibits Akt1/Akt2. The inhibition appears 
to be pleckstrin homology (PH) domain-dependent. It does not exhibit any 
inhibitory effect against PH domain-lacking Akts (10). 
This drug was dissolved under sterile conditions in DMSO and stored at -80°C.  
 
NVP-BEZ 235: 
 
 
 
 
 
 
 
 
 Figure 21: Molecular structure of NVP-BEZ 235 (Maria et al., 2008). 
 
 
NVP-BEZ 235 (Chemietek; 915019-65-7; Figure 21) is a dual PI3K and mTOR 
Inhibitor. NVP-BEZ 235 is an imidazo[4,5-c]quinoline derivative that inhibits 
PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these 
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enzymes. In human tumor cells this drug was able to block the dysfunctional 
activation of the PI3K pathway, including G1 arrest (Maria et al., 2008). 
This drug was dissolved under sterile conditions in DMSO and stored at -80°C. 
 
AZD6244: 
  
 
 
 
 
 
 
    
Figure 22: Molecular structure of AZD6244 (Yeh et al., 2007). 
 
AZD6244 or ARRY-142886 (Chemietek; CT-A6244; Figure 22) is a potent and 
selective MEK1/2 inhibitor and moreover it potently inhibits the basal ERK1/2 
phosphorylation. 
This drug was dissolved under sterile conditions in DMSO and stored at -80°C  
(Yeh et al., 2007). 
 
U0126: 
 
 
 
 
 
 
 
Figure 23: Molecular structure of U0126 (Favata et al., 1998). 
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U0126 (Cell Signaling; NEB9903; Figure 23) was dissolved under sterile 
conditions in DMSO and stored at -80°C. It directly and selectively inhibits 
mitogen activated protein kinase kinases MEK1 and MEK2 (Favata et al., 
1998). 
 
AS703026: 
 
 
 
 
 
 
 
Figure 24: Molecular structure of AS703026 (11). 
 
AS703026 (kind gift from Merck Serono; Figure 24) is a small- molecule 
inhibitor of MEK1 and MEK2. It selectively binds to MEK1/2 and prevents the 
activation of MEK1/2 dependent effector proteins and transcription factors, 
which may lead to the inhibition of growth factor mediated cell signalling and cell 
proliferation.  
This drug was dissolved under sterile conditions in DMSO and stored at -20°C  
(11).  
 
2.3 Cell proliferation assay (EZ4U)  
 
2.3.1 Background 
 
This assay is a colorimetric assay used to measure cell proliferation. It is based 
on the activity of mitochondrial dehydrogenase enzymes in cells (Ahmadian et 
al., 2009).  
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3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) salt is 
reduced to colored formazan (Figure 25) by active mitochondria in viable cells 
(Liu Y et al., 1997).  
 
 
 
 
 
 
 
 
 
 
Figure 25: Reduction of 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) to formazan by mitochondrial reductase (Scudiero et al., 1988). 
 
 
2.3.2 Performance of EZ4U assay 
 
Cells were plated in 96-well plates, at a density of 1,5 x 105 cells per well, in 
100µl medium respective for the cell line, containing 10% FCS and PSG. After 
24 hours, the attachment was controlled microscopically. Then 100µl D-MEM or 
α-MEM without FCS and containing PSG as well as different concentrations of 
the above mentioned inhibitors was given to the attached cells. Controls were 
treated with solvent (DMSO) only. Blank wells contained only medium with 5% 
FCS and are without cells. 
Three wells were analyzed for each treatment condition. After 72 hours of 
incubation at 37°C and light protected, the non-radioactive cell proliferation and 
cytotoxicity assay termed EZ4U (Biomedica BI-5000, Vienna, Austria) was 
performed. Intact mitochondria of viable cells reduce uncoloured tetrazolium salt  
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into intensely coloured formazan derivates. This chemical reaction is detected 
as a colour change of the medium. First, one vial EZ4U substrate was dissolved 
in 2,5 ml activator and prewarmed to 37°C for 10 minutes. Then 20 µl/well of the 
EZ4U reagent was added. After two hours of incubation at 37°C, the 
absorbance was measured at 490nm against a 655nm reference wave length, 
on the microplate reader spectrophotometer (Bio-Rad Labortories Model 680). 
Dose response curves and IC50 values were calculated with SigmaPlot and 
Microsoft Excel. 
 
2.4 Protein analysis (Western blotting) 
 
2.4.1 Background 
 
 
Figure 26: Workflow of the Western Blot (12; 13). 
 
 
Western blotting (Figure 26) is an analytical technique, which is used to identify 
proteins. This assay is based on the ability of these proteins to bind to a specific  
  Material and Methods 
 
 
49 
 
antibody. With this method the size of the interesting proteins can be 
determined, by comparison to the sizes of a mixture of prelabelled marker 
proteins (kDa). Moreover, it gives an information of protein expression, by the 
comparison of an untreated sample (control). Therefore, sodium dodecylsulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) is performed. This method 
separates proteins in a polyacrylamide gel matrix according to their size, in the 
presence of an electric current. Low percentage (8-10%) gels separate larger 
proteins, whereas higher percentage (15-20%) gels separate smaller proteins. 
SDS is given to the protein sample. It binds to proteins and neutralizes the 
electrical charge. This is necessary to separate them by size and not by charge. 
To reduce disulphide bridges in proteins, which is necessary linearize them for 
a separation by size, all protein samples were boiled in mercaptoethanol-
containing loading buffer at 95°C. To separate proteins, two different 
polyacrylamide gels were used. One is called stacking gel and the other running 
or separating gel. The stacking gel with a pH of 6,8 is used to pack proteins 
together, after loading. The running gel has a pH of 8,8 and is used at the 
bottom to separate proteins. Polyacrylamide gels are formed by the 
polymerization of two compounds, acylamide and N,N-methylenebis-acrylamide 
(Bis). Bis serves as a cross-linking agent in these gels. Polymerisation is 
initiated by the addition of ammonium persulfate together with 
tetramethylethylenediamine (TEMED). After electrophoresis, separated proteins 
were transferred in an electrical field from the gel to a membrane. Therefore, a 
wet electrotransfer was used during which the negatively charged proteins 
traveled towards the positively charged electrode and were bound by the 
membrane. Then the membrane with the bound proteins was blocked with 
bovine serum albumin (BSA), to prevent non-specific background. This is 
followed by washing steps. Then the membrane is incubated with the first 
antibody solution, directed against a specific protein. Then secondary antibody, 
which is directed against a species-specific region of the first antibody, is used. 
Normally this secondary antibody is linked to horseradish peroxidase, a reporter 
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enzyme, which cleaves an added substrate. This results in a detectable light 
signal (enhanced cehmiluminescence), (14;15). 
 
2.4.2 Protein extractions 
 
5x105 cells were plated in 60x15mm tissue culture dishes. Cells were cultured in 
7ml respective growth medium per well, supplemented with 5% FCS, 100U/ml 
penicillin, 100μg/ml streptomycin and 2mM L-glutamin. They were allowed to 
adhere over night. Then the treatment with the respective drug (see used drugs 
2.) started. Moreover, a DMSO solvent control culture was included. Cells were 
exposed for 6 hours at 37°C and protected from light, because drugs are light 
sensitive. After the incubated time period, cells were checked under the light 
microscope to determine their degree of confluence and apoptosis. 
 
2.4.2.1 RIPA Lysis 
 
All of the following steps were done on ice. Before lysis, culture media was 
removed and cells were washed twice with cold PBS. Then the remaining PBS 
was carefully removed from the dish and 80µl freshly prepared RIPA+ lysis 
buffer (Table 3 and 4 ingredients of RIPA and RIPA+) was added to the dish. 
Thereafter, cells were left on ice for 5 min and collected by scraping with a 
sterile scraper. Then, these lysates of the cells were transferred into an 
Eppendorf tube and vortexed for several times. After vortexing, the lysates were 
centrifuged at 12.500rpm at 4°C for 30min. The pellet was discarded and the 
supernatant was saved at -20°C for the protein assay. 
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Table 3: Ingredients of RIPA Lysis Buffer; it was adjusted to pH 7,4, filled up with water 
to 95ml and stored at 4°C. 
Reagent  MW 
Stock 
Concentration 
Volume 
Final 
Concentration 
Na Cl 58.44 5M 3ml 150mM 
Tris pH 7,4                               121.14           1M 5ml 50mM 
DOC  
(Na-deoxycholate) 
414.6 10% 5ml 0,5% 
EGTA 380.4 50mM 4ml 2mM 
EDTA pH 7,4 372.2 50mM 10ml 5mM 
NaF 41.99 500mM 6ml 30mM 
β-Glycero- 
phosphate pH7,2 
216 400mM 10ml 40mM 
Tetrasodium- 
pyrophosphate 
446.06 100mM 10ml 10mM 
Benzamidine 156.6 30mM 10ml 3mM 
Nonidet P-40  pure 1ml 1% 
 
 
Table 4: Ripa+ Lysis Buffer; it has to be prepared freshly before use. 
Reagent           Volume 
RIPA            1.90ml 
200mM Na-Orthovanadate              20µl 
25xComplete stock solution (Protease Inhibitor Cocktail)              80µl 
 
 
2.4.2.2 Protein Quantification 
 
The determination of the protein concentration of each sample was done with 
the BioRad Protein Assay Kit II (Bio-Rad 500-0112). This assay was 
accomplished in a 96 well plate. First, a 10mg/ml bovine serum albumine (BSA) 
stock solution for protein standard was produced. Therefore, 10mg BSA was  
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dissolved in 1ml Aqua bidest., then this protein standard was serially diluted 1:2 
with RIPA+ to get 5, 2.5, 1.25, 0.625, 0.315, 0.15625 µg/µl protein standards. 
RIPA+ allone was used as a blank control. This assay was also done in 
triplicates. Then, 5µl of each standard was set up in a 96 well plate in increased 
concentrations or 5µl of the sample.  All following steps were done under light 
protection. Reagent Aʹ of this Protein Assay Kit II was freshly prepared by 
adding 1ml Reagent A (BioRad 5000113) to 20µl Reagent S (BioRad 5000115). 
Thereafter, 20µl of the Reagent Aʹ and 200µl Reagent B (BioRad 5000114) of 
this kit was added to each well, which contains samples or standards. After 
incubation for 20min the absorbtion was measured at 655/450nm with a 
microplate reader spectrophotometer (Bio-Rad Labortories Model 680). After 
this measurement, the protein concentration for each sample and standard 
curve was calculated using Microsoft Excel Software. Then the protein samples 
were stored in a 1x sample buffer at -20°C, at a final concentration of 1µg/µl. 
Therefore, the samples were diluted with three parts RIPA+ to a concentration 
of 1.33µg/µl and then one part 4x sample buffer (Table 5).  
 
Table 5: Ingredients of 4x Sample Buffer (Beta-mercaptoethanol was added just before 
use). 
Reagent MW Stock Volume 
Final 
Concentration 
Glycerol 92.09 pure 5ml 50% 
Tris-HCl, pH 6.8 121.14          1M 1.25ml 125mM 
SDS  20% 2ml 4% 
Bromophenol 
blue 
 1% 1.25ml 0.125% 
Beta-
mercaptoethanol 
 pure 0.5ml 5% 
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2.4.3 SDS- Polyacrylamide Gel Electrophoresis (PAGE) 
 
The sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
is used to separate the proteins according to their size by the use of a 10% 
separating gel and a 4% stacking gel (Table 6, 7 and 8). SDS is used to 
denature proteins. This detergent wraps around the polypeptide backbone, so 
the intrinsic charges of the protein becomes negligible compared to the negative 
charges contributed by SDS. After SDS treatment proteins become a rod like 
structure possessing a uniform charge density. This allows separating proteins 
according to their size by migration from the cathode to the anode (Ornstein L. 
et al 1964 and Davis B.J. et al 1964). The separating gel was carefully 
overlayed with Aqua bidest to avoid any air bubbles and was allowed to 
polymerize for 30-45min. After this time, Aqua bidest was poured off and 
remaining water was drained with a small filter paper. Then the 4% stacking gel 
was pipette up to the very top of the plates. The comb, which is used to form 10 
slots in the gel, was slightly inserted. The stacking gel required 20min for 
polymerization. The plates with the polymerized gels were inserted into the gel 
holder cassette (Bio-Rad 1703931) and then into the electrophoresis chamber. 
A 1x running buffer containing 25mM Tris, 192mM glycine and 0,1% SDS in 
Aqua bidest  was added to  the chamber. Each protein sample was then boiled 
for 10min at 95°C for denaturation. Afterwards, 30µg protein per slot was 
loaded and 2µl of the molecular weight marker (Magic Mark XP from Invitrogen 
LC5602) were loaded into an extra slot. Then electrophoresis was conducted 
with constantly 90V. It is important to stop electrophoresis before proteins run 
off the gel. But proteins are mostly colourless. Therefore, bromophenol blue, 
which was added to the proteins with the 4x sample buffer (see 2.4.2.2.), is 
used as a marker dye. It is a small molecule, which is negatively charged and 
moves towards the anode. It moves ahead of the most proteins, because it is 
very small and when it reaches the anode at the end of the gel, electrophoresis 
is stopped.   
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Table 6: Ingredients of 30% Acrylamide/Bis solution. 
Reagent Volume Source 
40% Acrylamide 11,1ml Bio-Rad 1610140 
2% Bis Solution 3ml Bio-Rad 1610142 
Aqua bidest. 0,9ml  
Total volume of 30% A/B 15ml  
 
 
Table 7: Ingredients of the 10% seperating gel. 
Reagent Volume  Source 
30% A/B (Table 6) 6.7ml  
Aqua bidest. 8ml  
1.5M Tris 8.8  5ml Bio-Rad 1610798 
10% SDS 200µl Bio-Rad 1610418 
10% APS 100µl Bio-Rad 1610700 
Temed pur 10µl Bio-Rad 1610800 
 
 
Table 8: Ingredients of the 4% stacking gel. 
Reagent Volume Source 
30% A/B (Table 6) 1.673ml  
Aqua bidest. 7.46ml  
0.5M Tris pH 6.8 3.15ml Bio-Rad 1610799 
10% SDS 125µl Bio-Rad 1610418 
10% APS 125µl Bio-Rad 1610700 
Temed pur 12.5µl Bio-Rad 1610800 
 
 
2.4.4 Electrotransfer 
 
After the proteins were separated according to their molecular weight, they were 
transferred to a polyvinylidene difluoride (PVDF) membrane (NEF 153196). 
Blotting rely upon current and a transfer buffer solution, which drive proteins 
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onto the PVDF membrane. To blot the proteins from the gel to the membrane 
an electrical field was used. Negatively charged proteins migrate from the 
cathode to the anode. It is necessary that the membrane is located between the 
gel and the anode. Proteins bind to the membrane because of hydrophobic 
interaction (Burnette W.N. et al 1981). Thereafter, the membrane was marked 
and shortly soaked in pure methanol. Then a blotting sandwich was made 
(Figure 27). The used filter papers and scotch brites were soaked in a 
precooled transfer buffer, which contains 150mM glycine, 50mM Tris pH8.3, 
0.05% sodium dodecylsulfate (SDS) and 20% methanol. To remove air bubbles 
from the sandwich, a pipet was rolled over it. Then the blotting sandwich was 
placed into the blotting chamber. This chamber was filled with the precooled 
transfer buffer. One small stirring rod was placed into this chamber. The 
electrotransfer was performed over night at constant current of 290mA, at 4°C.  
 
 
Figure 27: Assembly of the blotting sandwich. 
 
 
2.4.5 Immunostaining of the blotted membranes 
 
After the electrotransfer, the blotting sandwich was disassembled. The PVDF 
membrane was cut exactly into the size of the gel. Then the non-specific protein 
binding sites on the membrane had to be blocked. Therefore, a blocking 
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solution was made, which contains 4% bovine serum albumin (BSA, Fluka 
05480) in 1xTris buffered saline (TBS, Bio-Rad 1706435). This TBS contains 
0.1M Tris pH 7.5, 0.5M NaCl and Aqua bidest, supplemented with 0,1% 
Tween20 (Bio-Rad 1706531), TBS together with Tween is abbreviated as TBS-
T. 4% heat incativated fetal calf serum (Gibco 10270-106) was added to TBS-T 
and BSA, to achieve the blocking solution. The cut membrane was incubated 
for one hour in blocking solution, at room temperature, during shaking. 
Then the blocking solution was removed and the membrane was washed three 
times with TBS-T for 5min each. Afterwards the first antibody solution, which 
consisted of 1xTBS-T with 1% blocking solution, 0,05% Na-azide (for longer 
storage of the solution) and the respective antibody (Table 9), was added to the 
membrane. Incubation with the first antibody was over night at 4°C (Figure 28). 
After this incubation the first anibody solution was removed and the membrane 
was washed, twice for 5min and twice for 10min with TBS-T. Then the 
secondary antibody solution, which consisted of 1xTBS-T with 1% blocking 
solution and in which a HRP conjugated antibody (Table 10) was diluted, was 
added to the membrane for one hour shaking at room temperature. Thereafter, 
the secondary antibody solution was removed and the membrane was washed 
four times with TBS-T (twice for 5min and twice for 10min) and four times with 
TBS (twice for 5min and twice for 10min). Primary antibodies against α/β- 
Tubulin or Actin were used as loading control. 
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Figure 28: Detection of proteins by the use of two different antibodies. Peroxidase, 
which is linked to the sencondary antibody, reacts with ECL-reagent, so that the 
antigen becomes visible (Hawkes et al., 1982). 
 
Then for enhanced chemiluminescence (ECL), the membrane was incubated 
with a mixture of 2ml detection solution A and 2ml detection solution B (Pierce 
32106) for 5 minutes. This solution reacts with the horseradish peroxidase, 
which was conjugated to the secondary antibody. Horseradish peroxidise 
catalyses the oxidation of luminol to 3-aminophthalate, which is accompanied 
by emission of light (Veitch N.C. et al, 2004). This reaction occurs at the place 
where the specific antigen is located on the PVDF membrane. Detection occurs 
by the exposure of the membrane to Hyperfilm ECL high performance 
chemiluminescence film from Amersham (RPN3103K). 
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Table 9: List of primary antibodies used for the detection of proteins of interest.  
Antibody Species Dilution Source 
AKT1,2,3 Rabbit 1:1000 
Cell Signalling 9272, 
60kD,polyclonal Antibody 
pAKT(Ser473) Rabbit 1:1000 
Cell Signalling 9271, 
60kD, polyclonal Antibody 
pAKT(Thr308) Rabbit 1:1000 
Cell Signalling 9275, 
60kD, polyclonal Antibody 
ERK1,2 Rabbit 1:3000 
Upstate 06-182 
P44/42 MAP Kinase, 
polyclonal Antibody 
pERK1,2 
(Thr202/Tyr204) 
Rabbit 1:1000 
Cell Signalling 9101 
Phospho-p44/42 MAP                 
Kinase  polyclonal Antibody 
MEK1,2 Rabbit 1:1000 
Cell Signalling 9122 
45kD, polyclonal Antibody 
pMEK1,2 
(Ser217/221) 
Rabbit 1:1000 
Cell Singalling 9121, 
45kD, polyclonal Antibody 
S6 Rabbit 1:1000 
Cell Signalling 2217 
32kD, monoclonal Antibody 
pS6(Ser240/244) Rabbit 1:2000 
Cell Signalling 2215 
32kD, polyclonal Antibody 
 
α/β Tubulin Rabbit 1:1000 
Cell Signalling 2148 
55kD, polyclonal Antibody 
β Actin Goat 1:1000 
Santa Cruz Biotechnology 
sc-1616, 43kD, polyclonal   
Antibody   
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Table 10: List of secondary antibodies. 
Antibody Dilution Source 
Donkey-anti- 
rabbit 
1:15000 
Promega V7591, 
horseradish peroxidase 
(HRP) linked 
Donkey-anti- 
goat 
1:15000 
Santa Cruz Biotechnology sc2020 
horseradish peroxidase 
(HRP) linked 
 
 
2.4.6 Stripping of the membranes 
 
After the detection of the proteins of interest, the membrane can be stripped, to 
detach all antibodies from the proteins in order to make the membrane suitable 
for another round of incubation with antibodies. For that reason a 1x stripping 
solution (Table 11) was prepared. Twenty ml of this stripping solution and 200µl 
β-Mercaptoethanol were added to the blot. Stripping was accomplished at 50°C 
in a water-bath for 20min, with constant shaking. Afterwards the membrane was 
washed with TBS-T, twice for 5min and twice for 10min. Then the blot was 
blocked with blocking solution containing 4% FCS for one hour and further 
processed for immunostaining in the regular way as described above (2.4.5.). 
  
 Table 11: Ingredients of the stripping solution. 
Reagent Quantity 
SDS 10g 
1M Tris pH 6.7 31.3ml 
Aqua bidest. filled up to 500ml 
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2.5 Statistical analysis 
 
2.5.1 Analysis of variance (ANOVA) 
 
Analysis of variance is a general method for statistical estimation of different 
means between more than two groups. Variance analysis is used to test, if 
variance between two groups is greater than variance inside these groups. 
Therefore, it could be analysed if these groups differ significantly or not. In the 
two factorial variance analysis two factors are considered (16). Anova was 
performed using Microsoft Excel 2007. 
  
Yijk= µ+αi+βj+(αβ)ij+eijk              eijk~ N(0,σ
2)  i=1,....,I,   j=1,....,J,    
k=1,....,K 
 
µ..........global expectancy 
αi.........effect of i-factor  
βj.........effect of j-factor 
(αβ)ij....effect of interaction 
eijk.......random difference of the mean pro factor combination 
 
2.5.2 Scheffé-Test 
 
This analysis is done, only when anova yields significance. It compares all 
possible subgroups of means (17). Scheffé-Test was performed using Microsoft 
Excel 2007. 
 
µi..........mean i 
µj..........mean j 
 sin........standard deviation 
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F......... F-distribution 
n.........sum of single values of all groups 
k.........sum of all means 
 
2.5.3 Student’s t-Test 
 
This statistical test assess whether the means of two groups statistically differ 
from each other, used to compare the means of two groups. The top part of the 
ratio is the difference between the two means. The bottom part is a measure of 
the variability of the groups (Paul D. Lewis, R for Medicine and Biology). 
Student’s t-Test was performed using Microsoft Excel 2007.  
 
  and 
 
 
 
SX1X2 .........grand standard deviation 
1................group one 
2................group two 
n................number of participants  
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3 Results          
3.1 Comparison of pelitinib sensitivity and resistance in 
different breast cancer cell lines 
 
In breast cancer, the epidermal growth factor (EGF) receptor (EGFR) or ErbB 
family is very important for its pathogenesis (Olayioye et al., 2000). Previous 
experiments showed that the two breast cancer cell lines T47D and SKBR3 
respond in different ways to EGFR/ErbB-2 receptor tyrosine kinase inhibitor 
pelitinib. T47D was resistant, whereas SKBR3 was sensitive against this 
inhibitor (Brünner-Kubath et al., in press). To define further breast cancer cell 
lines that respond either resistant or sensitive against pelitinib, MCF7, BT474 
and MDA-MB 231 were tested with in vitro growth assays in addition to the two 
established cell lines. Cells were treated for 72 hours with 0-20µM pelitinib 
(Figure 29) and IC50 values were determined (Figure 30). 
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Figure 29: Growth curves from a panel of 5 different breast cancer cell lines 
treated with pelitinib. SKBR3, BT474, MCF7, MDA-MB 231 and T47D cell lines were 
exposed to 0-20µM pelitinib for 72 hours. Cell proliferation was analysed by EZ4U. 
Means ± SD, n≥3. 
 
The findings indicate that MDA-MB-231, MCF7 and T47D cells exhibit high IC50 
values (Figure 30 and Table 12). Especially T47D, with an IC50 value of 
15,61µM was very resistant. In contrast, SKBR3 and BT474 cells showed much 
lower IC50 values, which indicate that these two cell lines are more sensitive 
against the inhibitor. Moreover, this outcome supports earlier findings of 
resistance and sensitivity in T47D and SKBR3, respectively. SKBR3 reveal an 
IC50 of 3,65µM and BT474 an IC50 of 4,63µM, which are the lowest IC50 values 
in the tested panel of cell lines. However, the other cell lines MDA-MB 231 and 
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MCF7 reveal higher IC50 values ranging from 8,41µM to 9,72µM, but they could 
not reach such a high IC50 value than T47D cells. 
                   
Cell line IC50  
SKBR3 3,65µM 
BT474 4,63µM 
MCF7 8,41µM 
MDA-MB 231 9,72µM 
T47D 15,61µM 
 
 
 
 
Figure 30 and Table 12: IC50 value of 5 different cell lines exposed to pelitinib.   
Effects on cell growth were determined by EZ4U of 72 h inhibitor treatment. 
 
3.2 ErbB downstream signalling profiles from a panel of breast 
cancer cell lines exposed to pelitinib 
 
After the findings we achieved in growth assays done with pelitinib, Western 
blot experiments using the three cell lines BT474, MCF7 and MDA-MB 231 in 
the presence or absence of pelitinib were performed in order to find out whether 
these cell lines reveal downstream Akt and Erk activation profiles that are 
analogous to the previously characterized patterns obtained from pelitinib 
sensitive SKBR3 and pelitinib resistant T47D cells (Brünner-Kubath et al., in 
press). 
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Figure 31: Breast cancer cell lines BT474, MCF7 and MDA-MB 231 exposed to 
phospho-AKT (Ser473), phospho-AKT (Thr308), AKT, phospho-ERK1,2 
(Thr202/Tyr204) and ERK1,2 antibodies. Cells were grown in 60mm dishes 
containing medium with 5% FCS for 24h. The cultures were treated with 0,1µM, 1µM, 
2µM, 4µM and 8µM pelitinib as well as only with the solvent (DMSO) without pelitinib 
for 6h. Cell lysates were collected as described in material and methods. β-Actin was 
used as a loading control.  
 
This panel of cell lines were cultivated as described in Material and Methods, 
exposed for 6h to different concentrations of pelitinib and afterwards results 
were detected using Western blotting analysis (Figure 31).      
These findings indicate that BT474 cell lines respond sensitive to the used drug. 
They show a reduction of pAKT (Ser473) and pAKT (Thr308) already at a 
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concentration of 0,1µM inhibitor. Likewise, the pERK1,2 (Thr202/Tyr204) level is 
very low at this concentration, but it does not completely disappear until the 
highest concentration of the drug. This result goes along with the finding 
obtained in growth assay analysis, where BT474 seems to be sensitive against 
pelitinib.      
Interestingly, MCF7 shows a very low level of pAKT (Ser473) and pAKT 
(Thr308), in the untreated control. However, treatment with pelitinib, leads to an 
enhanced pAKT level, especially at concentrations of 4µM and 8µM inhibitor. 
Furthermore, the pERK1,2 (Thr202/Tyr204) level accumulates in this cell line. 
These findings correspond to growth assay analysis done with pelitinib, in which 
MCF7 proved to be resistant to this drug.       
   
MDA-MB 231 cells exhibit low concentrations of pAkt (Ser473) and pAkt 
(Thr308) already in the untreated control and no further reduction by exposure 
to pelitinib. In contrast, this cell line reveals a high level of pErk1/2 
(Thr202/Tyr204), which is reduced only at high concentration of the inhibitor.  
     
 
3.2.1 Investigation of the importance of the MAPK pathway in MDA-MB 231 
cells 
 
Due to the results achieved from Western blotting analysis of MDA-MB 231 
cells, we suggested that the MAPK pathway, compared to the PI3K system, 
may be more important in this cell line. These cells show high pERK1,2 
(Thr202/204) level, but very low pAKT concentrations in the untreated control. 
Therefore, a growth assay analysis with the two MEK inhibitors U0126 and 
AZD6244 was done (Figure 32). To determine if decreased growth of this cell 
line will occur in response to inhibition of MEK. But a treatment of these cells 
with the inhibitor U0126 revealed no inhibition. The IC50 value could not be 
reached.  
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Exposure to the second inhibitor AZD6244 showed a high IC50 value of 
14,15µM. According to these results, both MEK inhibitors do not significantly 
affect in vitro growth of this cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Treatment of MDA-MB 231 with U0126 and AZD6244.    
Cells were exposed to 0-20µM AZD6244 and 0-40µM U0126 for 72h. Proliferation was 
analysed by EZ4U. Means ± SD, n≥3. 
 
 
3.3 Determination of the fundamental ErbB downstream 
signalling pathways in SKBR3 and T47D 
 
3.3.1 Inhibition of the phosphatidylinositol-3-kinase pathway 
 
The mammalian target of rapamycin (mTOR) belongs to the 
phosphatidylinositol kinase-related kinase family and plays central role in 
regulation of protein synthesis, cell growth and proliferation control. In response 
to mitogen stimulation, mTOR regulates translation through two distinct 
pathways, the ribosomal p70S6 kinase and the eukaryotic translation initiation 
factor 4E (eIF4E) inhibitor binding protein 1 (4EBP1) (Sun SY. et al., 2005).  
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Hence, we wanted to examine how the pelitinib sensitive and resistant cells 
SKBR3 and T47D respond to inhibition of mTOR, to determine whether the 
PI3K pathway is important or not for these two cell lines. Therefore, a growth 
assay with rapamycin, a selective mTOR inhibitor, was performed (Figure 33).  
 
 
 
 
 
 
 
 
 
Figure 33: The growth effects of rapamycin in SKBR3 and T47D cells.   
Cell lines were exposed to 0-10µM rapamycin for 72h. Proliferation was analysed by 
EZ4U. Means ± SD, n≥3. 
 
Rapamycin shows good inhibitory effects on T47D cells compared to SKBR3 
cells. The IC50 value in rapamycin treated T47D cells lies at 0,33µM. SKBR3 
cells do not respond as good as T47D cell line on mTOR inhibition. The IC50 
value for SKBR3 is 4,09µM. These results indicate that rapamycin exerts much 
better growth inhibitory effects on T47D when compared to SKBR3 cells. 
Rapamycin only inhibits mTOR, therefore another inhibitor called NVP-BEZ 
235, which acts as a dual mTOR and PI3K inhibitor, was used to treat SKBR3 
and T47D cells (Figure 34). Several isoforms of the PI3K family are implicated 
in pathologic processes and diseases. It facilitates the phosphorylation of Akt, 
which is a central effector of this pathway (Serra et al., 2008). 
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Figure 34: The growth effects of NVP-BEZ 235 on T47D and SKBR3 cells.    
Cells were exposed to 0-1µM NVP-BEZ 235 for 72h. Effects on growth were 
determined by EZ4U. Means ± SD, n≥3. 
 
Results from growth assay performed with NVP-BEZ 235 show, that the dual 
inhibitor acts strongly on both cell lines. T47D as well as SKBR3 reveal low IC50 
values. However, T47D cells show a stronger response to the inhibitor than 
SKBR3 cells, with an IC50 value of 0,08µM, which is very low, whereas the IC50 
value of NVP-BEZ 235 against SKBR3 cells with 0,29µM is nearly four times 
higher. Previous studies showed that NVP-BEZ 235 had different effects 
dependent on the used concentration. The inhibition of mTOR predominates at 
low concentrations, but dual mTOR/PI3K blockade occur at higher drug 
concentrations. Hence, we next used a direct Akt inhibitor called Akti-1,2 to treat 
these two cell lines (Figure 35). Akt is a central effector of the PI3K/Akt 
pathway. It promotes for example protein synthesis and cell growth by 
alleviating suppression of mTOR (Serra et al., 2008). 
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Figure 35: The growth effects of Akti-1,2 on SKBR3 and T47D cells.       
The two cell lines were exposed to 0-2,5µM Akti-1,2 for 72h. Cell growth was analysed 
by EZ4U. Means ± SD, n≥3. 
 
Akti-1,2 drug exposure shows good inhibitory effects on T47D (IC50 0,86µM), 
but is less efficient in SKBR3 (IC50 1,9µM). Akti-1,2 was less potent than NVP-
BEZ 235 or rapamycin. These results indicates that dual inhibition of both 
mTOR and PI3K by NVP-BEZ 235 shows much more inhibitory effect than 
single inhibition of mTOR by rapamycin or of Akt by Akti-1,2, in these two cell 
lines. 
 
3.3.2 Inhibition of the mitogen–activated protein kinase pathway 
 
MEK is part of the mitogen-activated protein kinase pathway. It activates 
ERK1/2 by phosphorylation. Activated ERK1/2 phosphorylates a wide range of 
protein substrates including transcriptional and apoptosis regulators (Whyte J. 
et al., 2009). To determine if MEK1/2 inhibitors are also able to inhibit growth of 
breast cancer cells, growth assays with the three MEK1/2 inhibitors AZD6244, 
U0126 and AS703026 were performed (Figure 36-38).  
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Figure 36: The growth effects of AZD6244 on SKBR3 and T47D cells.         
Cells were exposed to 0-20µM of the inhibitor for 72h. Effects on cell growth were 
determined by EZ4U. Means ± SD, n≥3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: The growth effects of U0126 on SKBR3 and T47D cells.    
Cells were treated with 0-40µM U0126 for 72h. Proliferation was analysed by EZ4U. 
Means ± SD, n≥3. 
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Figure 38:The growth effects of AS703026 on SKBR3 and T47D cells .   
The two cell lines were exposed to 0-20µM inhibitor. Effects on cell growth were 
determined 72h after treatment by EZ4U. Means ± SD, n≥3. 
 
Treatment of SKBR3 and T47D cells with these three MEK inhibitors revealed 
no significant inhibition of growth in these cell lines, because IC50 value of both 
cell lines lies over 20µM with AZD6244, U0126 and AS703026.  
 
Together, these findings in SKBR3 and T47D cells treated with PI3K or MAPK 
inhibitors showed that both cell lines respond much more sensitive to inhibition 
of PI3K- than of MAPK pathways (Figure 39).  
 
 
 
 
 
 
 
 
 
 
AS703569 (µM)
c
e
ll
 n
u
m
b
e
r 
(%
 o
f 
c
o
n
tr
o
l)
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
0 5 10 20
SKBR3
15
AS703569 (µM)
c
e
ll
 n
u
m
b
e
r 
(%
 o
f 
c
o
n
tr
o
l)
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
0 5 10 20
T47D
15
      Results 
 
 
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure39: IC50 values of SKBR3 and T47D treated with different inhibitors.  
Cells were exposed to PI3K pathway inhibitors (Akti-1,2, rapamycin or NVP-BEZ 235) 
or to MAPK pathway inhibitors (AZD6244, U0126 or AS703026). IC50 values were 
determined after 72h of drug exposure. Statistical significance between SKBR3 (grey) 
and T47D (black) was determined by two-tailed Student´s t-Test, *** indicates 
significant difference at p<0,001. 
 
 
3.4 Effects of PI3K pathway inhibitors on AKT, ERK and S6 in 
the two cell lines SKBR3 and T47D 
 
3.4.1 Influence of mTOR inhibition in the pelitinib sensitive and resistant 
cell lines 
 
To determine the downstream signalling effects of mTOR inhibition by 
rapamycin, Western blot analysis in the presence and absence of this drug in 
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both cell lines was done. Growth assay analysis of SKBR3 treated with 
rapamycin showed low growth inhibitory effects. Treatment of T47D in contrast 
worked very good and showed potent growth inhibitory effects. Therefore, it was 
necessary for us to determine how this inhibitor affects the downstream 
signalling pathway in these cell lines. SKBR3 and T47D were exposed to 0,1-
10µM rapamycin for 6h (Figure 40 and 41). Antibodies against AKT, ERK and 
S6 or their phosphorylated forms were used. β-Actin was utilized as a control, 
for equal loading and efficient protein transfer on  PVDF membranes.  
 
 
 
Figure 40: Separated total protein from SKBR3 cells treated with rapamycin was 
labelled with phospho-AKT (Ser473), phospho-AKT (Thr308), AKT, phospho-
ERK1,2 (Thr202/Tyr204), ERK1,2, S6 and phospho-S6(Ser240/244) antibodies.  
Cells were allowed to attach over night in 5% FCS in 60mm dishes. Cultures were 
treated with 0,1µM, 0,25µM, 0,5µM, 0,75µM, 1µM, 5µM and 10µM rapamycin as well 
as only with the solvent (DMSO) without the inhibitor. Cell lysates were collected after 
6h and β-actin was used as a loading control. 
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This result shows that pAKT (Ser473) and equally pAKT (Thr308) level 
decreases only in high concentrations of rapamycin. Likewise, pERK1,2 
(Thr202/Tyr204) level is reduced in high concentration of the drug. In contrast, 
pS6 (Ser240/244) is reduced at very low drug levels. These findings go along 
with growth assays done with rapamycin in this cell line, where SKBR3 
responds with low growth inhibition to this drug. Moreover as expected, this 
result shows that rapamycin inhibits mTOR, because the level of pS6 
(Ser240/244), which is located downstream of mTOR, decreases in low drug 
concentrations. 
 
 
Figure 41: Separated total protein from T47D cells treated with rapamycin was 
labelled with phospho-AKT (Ser473), phospho-AKT (Thr308), AKT, phospho-
ERK1,2 (Thr202/Tyr204), ERK1,2, S6 and phospho-S6 (Ser240/244) antibodies. 
Cells were grown in 60mm dishes containing medium with 5% FCS for 24h. Then cells 
were exposed to 0,1µM, 0,25µM, 0,5µM, 0,75µM, 1µM, 5µM and 10µM rapamycin as 
well as only with the solvent (DMSO) without the inhibitor. Cell lysates were collected 
after 6h and β-actin was used as a loading control. 
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Treatment of T47D cells with rapamycin leads to an increasing level of  
pAKT (Thr308) and also of pAKT (Ser473) but less stronger. Moreover, ERK1,2 
phosphorylation level is minor decreased in high drug concentrations. The pS6 
(Ser240/244) level is reduced already at a inhibitor concentration of 0,1µM. This 
cell line is sensitive against growth inhibition by rapamycin, which goes along 
with the results achieved in Western blotting, because pAKT (Ser473) is very 
low as well as pS6 (Ser240/244) level.  
 
3.4.2 Dual mTOR and PI3K inhibition in SKBR3 and T47D cell lines 
 
Inhibition with rapamycin in the pelitinib resistant cell line T47D showed some 
good effects, to overcome the resistance, but rapamycin inhibits only mTOR. To 
examine how dual inhibition of mTOR and PI3K influences downstream 
signalling in SKBR3 and T47D cell lines, Western blotting with NVP-BEZ 235 
was done. Both cell lines were treated with 0-1µM inhibitor for 6h. Thereafter, 
Western blotting was done (Figure 42 and 43) and β-actin was used as a 
loading control. Exposure of SKBR3 cell lines to NVP-BEZ 235 revealed a 
dose-dependent increasing level of pAKT (Thr308) up to 0,075µM which then 
strongly decreased at higher inhibitor concentrations. pAKT (Ser473) decreases 
already at lower inhibitor concentrations. The level of pS6 (Ser240/244) is 
reduced already at the lowest drug concentration used. Phosphorylated S6 is 
located downstream of mTOR and decreases already at very low 
concentrations of NVP-BEZ 235. Phosphorylation of AKT increases at low, but 
then decreases at higher concentrations of NVP-BEZ 235. This finding goes 
along with the results achieved from Serra et al., 2008, which indicate that this 
dual inhibitor blocks mTOR at very low concentrations and both mTOR and 
PI3K in high concentrations and is due to a negative regulatory feed-back loop 
from mTOR to PI3K. The level of pERK1,2 (Thr202/Tyr204) increased upon 
NVP-BEZ 235-mediated inhibition of mTOR and PI3K.  
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Figure 42: SKBR3 cells treated with the dual mTOR and PI3K inhibitor NVP-BEZ 
235 and labelled with phospho-AKT (Ser473), phospho-AKT (Thr308), AKT, 
phospho-ERK1,2 (Thr202/Tyr204), ERK1,2, S6 and phspho-S6 (Ser240/244) 
antibodies.   
Cells, which were grown in 60mm dishes containing medium with 5% FCS, were 
treated for 6h with 0,001µM, 0,025µM, 0,05µM, 0,075µM 0,1µM, 0,5µM and 1µM NVP-
BEZ 235 or with the solvent (DMSO) only. Cell lysates were collected as described in 
Material and Methods. β-actin was used as a loading control.  
 
Treatment of the pelitinib resistant cell line T47D with NVP-BEZ 235 showed 
that the pAKT (Ser473) level is strongly reduced at a concentration of 0,05µM. 
However, the pAkt (Thr308) level is increased at low inhibitor concentrations; 
only at high drug levels a reduction is seen. This might be caused by the 
differential affinity of the inhibitor for its two target kinases, which is significantly 
higher for mTOR than for PI3K. Thus mTOR becomes inhibited at very low drug 
concentrations already, whereas PI3K inhibition occurs only at much higher 
doses of NVP-BEZ 235 (Serra et al., 2008). The phosphorylation level of S6 is 
very intense in the untreated control, but pS6 level strongly decreases after  
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0,01µM NVP-BEZ 235 treatment and nearly disappears at higher 
concentrations. However, even at the highest concentration it could not be 
totally wiped out. At low concentrations of NVP-BEZ 235, an increase of 
pErk1/2 (Thr202/204) level was observed, but it decreased at higher 
concentrations of the dual inhibitor. 
 
 
Figure 43: Pelitinib resistant cell line T47D exposed to NVP-BEZ 235, a dual 
mTOR and PI3K inhibitor, labelled with phospho-AKT (Ser473), phospho-AKT 
(Thr308), AKT, phospho-ERK1,2 (Thr202/Tyr204), ERK1,2, S6 and phspho-S6 
(Ser240/244) antibodies. Cells were grown in 60mm dishes containing medium with 
5% FCS for 24h. Afterwards, cells were treated for 6h with 0,001µM, 0,025µM, 0,05µM, 
0,075µM 0,1µM, 0,5µM and 1µM NVP-BEZ 235 or well as with the solvent (DMSO) 
only. Cell lysates were collected as described in Material and Methods. β-actin was 
used as a loading control.  
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3.4.3 Determination of signalling effects through inhibition of AKT in T47D 
and SKBR3 cells 
 
Inhibition of these two cell lines with the mTOR/PI3K inhibitor NVP-BEZ 235 
reduces downstream pS6 more efficiently than AKT, which acts more upstream 
in the PI3K cascade. Thus, we wanted to determine how direct inhibition of AKT 
influences the signalling cascade in pelitinib resistant T47D and sensitive 
SKBR3 cells. Cells were cultivated for one day in medium containing 5% FCS, 
afterwards both cell lines were exposed to 0-5µM Akti-1,2 for 6h, followed by 
Western blot analysis (Figure 44 and 45). β-actin was used as a loading control.   
 
 
Figure 44: Breast cancer cell line SKBR3 exposed to Akti-1,2 was labelled with 
phospho-AKT (Ser473), phospho-AKT (Thr308), AKT, phospho-ERK1,2 
(Thr202/Tyr204), ERK1,2, S6 and phspho-S6 (Ser240/244) antibodies.    
Cells were grown in 60mm dishes containing medium with 5% FCS for 24h. The 
cultures were treated for 6h with 0,01µM, 0,05µM, 0,1µM, 0,75µM 0,5µM, 1µM, 2,5µM 
and 5µM Akti-1,2 with the solvent (DMSO) only. Cell lysates were collected as 
described in Material and Methods. β-actin was used as a loading control.  
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The level of pAKT (Ser473) is strongly decreasing at an inhibitor concentration 
of >0,1µM. Level of pAKT (Thr308) compared to pAKT (Ser473) is very low in 
the untreated control and decreases also at a concentration of >0,1µM Akti-1,2. 
Interestingly, the pERK1,2 (Thr202/Tyr204) level, which is very low in untreated 
SKBR3 cells, is enhanced by drug exposure. This may suggest that inhibition of 
AKT by Akti-1,2 lifts an inhibitory cross talk loop from the PI3K to the MAPK 
system. Moreover, the phosphorylation of S6 is reduced at inhibitor 
concentrations of >0,5µM.  
 
 
Figure 45: Breast cancer cell line T47D exposed to Akti-1,2 was labelled with 
phospho-AKT (Ser473), phospho-AKT (Thr308), AKT, phospho-ERK1,2 
(Thr202/Tyr204), ERK1,2, S6 and phspho-S6 (Ser240/244) antibodies.   
Cells were allowed to attach over night in 5% FCS in 60mm dishes. Cultures were 
treated for 6h with 0,01µM, 0,05µM, 0,1µM, 0,5µM, 0,75µM, 1µM 2,5µM and 5µM Akti-
1,2 as well as only with the solvent (DMSO) only. β-actin was used as a loading 
control. 
 
      Results 
 
 
81 
 
Results from inhibition of T47D cells with Akti-1,2 show that the level of AKT 
(Thr308) and AKT (Ser473) and S6 (Ser240/244) phosphorylation decreases at 
≥0,5µM drug concentrations. Equally to SKBR3 inhibition with this drug, the 
pERK1,2 (Thr202/Tyr204) level is increased with low Akti-1,2 dose and only 
decreases at high inhibitor concentrations. Western blotting analysis with Akti-
1,2 revealed that these two cell lines respond nearly in the same way to the 
inhibition of AKT. Compared to the other PI3K inhibitors, Akti-1,2 does not work 
as good as rapamyicn or NVP-BEZ 235 in reducing the pS6 level. This result 
goes along with growth assay analysis, where AKT inhibition alone showed not 
the same good growth inhibitory effects when compared to the other two PI3K 
pathway inhibitors in T47D cell lines.  
 
3.5 Effects of MAPK pathway inhibitors on MEK and ERK in the 
two cell lines SKBR3 and T47D 
 
Growth assay analysis with MEK1,2 inhibitors revealed, that they do not have 
any growth inhibitory effect on SKBR3 or T47D cells. This result leads to the 
suggestion that the MAPK pathway plays a minor role in the growth of these cell 
lines. In order to determine, if the used MEK1,2 inhibitors really lead to inhibition 
of this pathway. Western blot analysis of total proteins from SKBR3 and T47D 
cells exposed for 6h to the MEK1,2 inhibitors AZD6244, U0126 or AS703026 
was performed.  
 
3.5.1 Influence of AZD6244 on MAPK pathway signalling in the two 
pelitinib sensitive and resistant cell lines 
 
Previous growth analysis using AZD6244 showed no significant growth 
inhibitory effects on SKBR3 and T47D, with an IC50 value over 20µM. In order to 
analyze the inhibitory effect on the MAPK pathway signalling, Western blotting 
in both cell lines treated with AZD6244 was done. Cells were cultured as 
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described in Material and Methods. SKBR3 and T47D were exposed to 0-20µM 
AZD6244 for 6h (Figure 46 and 47). Antibodies against MEK and ERK or their 
phosphorylated forms were used. α/β- Tubulin was used as a control for equal 
loading and efficient protein transfer to PVDF membranes.  
 
 
 
Figure 46: Total protein from SKBR3 cells treated with AZD6244 were labelled 
with phospho-MEK1,2 (Ser217/221), MEK, phospho-ERK1,2 (Thr202/Tyr204) and 
ERK1,2 antibodies.  
Cells were allowed to attach over night in 5% FCS in 60mm dishes. Cultures were 
treated for 6h with 0,1µM, 1µM, 5µM, 10µM and 20µM AZD6244 or with the solvent 
(DMSO) only. α/β-Tubulin was used as a loading control. 
 
Results from Western blotting analysis of SKBR3 cells treated with the MEK1,2 
inhibitor AZD6244 interestingly showed an increasing level of MEK1,2 
phosphorylation also in the highest drug concentration, compared to a treatment 
with the solvent only. Moreover, the level of pERK1,2 (Thr202/Tyr204) is 
reduced strongly at a drug concentration of 0,1µM. This result shows that the 
inhibitor AZD6244 acts downstream of MEK1,2. Because an inhibition is only 
seen in the posphorylation of ERK1,2 which is located downstream of MEK1,2.  
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Figure 47: Total protein from T47D cells treated with AZD6244 were labelled with 
phospho-MEK1,2 (Ser217/221), MEK, phospho-ERK1,2 (Thr202/Tyr204) and 
ERK1,2 antibodies.          
Cells were allowed to attach over night with 5% FCS in 60mm dishes. Cultures were 
treated for 6h with 0,1µM, 1µM, 5µM, 10µM and 20µM AZD6244 or with the solvent 
(DMSO)only. α/β-Tubulin was used as a loading control. 
 
Western blotting analysis of T47D cells treated with AZD6244 showed nearly 
the same results like as compared to SKBR3 cells. Inhibitor exposure leads to 
an increasing level of pMEK1,2 (Ser217/221), but not with the same intensity 
than in SKBR3 cells. Furthermore, ERK1,2 phosphorylation is decreased at the 
lowest inhibitor concentration already. Therefore, AZD6244 acts also 
downstream of MEK1,2 in this cell line.  
 
3.5.2 Influence of U0126 on MAPK pathway signalling in the two pelitinib 
sensitive and resistant cell lines 
 
U0126 did not induce growth inhibition in pelitinib resistant T47D and sensitive 
SKBR3 cell lines. Analysis of the inhibitory effects of U0126 on the MAPK 
pathway, was done by Western blotting. Cells were cultivated for one day in 
medium containing 5% FCS. Afterwards, both cell lines were exposed to  
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0-80µM U0126 for 6h. α/β- Tubulin was used as a loading control (Figure 48 
and 49).         
 
 
 
Figure 48: Breast cancer cell line SKBR3 exposed to U0126 was labelled with 
phospho-MEK1,2 (Ser217/221), MEK, phospho-ERK1,2 (Thr202/Tyr204) and 
ERK1,2 antibodies. Cells were grown in 60mm dishes containing medium with 5% 
FCS for 24h. The cultures were treated for 6h with 10µM, 20µM, 40µM and 80µM 
U0126 or with the solvent (DMSO) only. Cell lysates were collected as described in 
Material and Methods. α/β-Tubulin was used as a loading control.  
 
Western blot analysis of SKBR3 cells exposed to the MEK1,2 inhibitor U0126, 
shows a dose-dependent increasing level of pMEK1,2 (Ser217/221). In 
contrast, phosphorylation of ERK1,2 decreases rapidly already at the lowest 
U0126 concentration. This result show that U0126 acts in the same way as 
AZD6244, namely downstream of MEK1,2.  
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Figure 49: Total protein from T47D cells treated with U0126 was labelled with 
phospho-MEK1,2 (Ser217/221), MEK, phospho-ERK1,2 (Thr202/Tyr204) and 
ERK1,2 antibodies. Cells were grown in 60mm dishes containing medium with 5% 
FCS for 24h. Then cells were exposed for 6h to 10µM, 20µM, 40µM and 80µM U0126 
or to solvent (DMSO) only. α/β-Tubulin was used as a loading control. 
 
T47D cells show a very low level of pMEK1,2 (Ser217/221), which was only 
very slightly elevated by U0126. In contrast, a strong reduction of pERK1,2 
(Thr202/Tyr204) can be seen already at the lowest dose of U0126.  
 
3.5.3 Influence of AS703026 on MAPK pathway signalling in the two 
pelitinib sensitive and resistant cell lines 
 
The third used MEK1,2 inhibitor, termed AS703026, did also not show any 
growth inhibitory effects on SKBR3 and T47D cells. To check the function of this 
drug, Western blotting in both cell lines was performed. Cells were cultured as 
described in Material and Methods. SKBR3 and T47D were exposed to 0-20µM 
AS703026 for 6h (Figure 50 and 51). Antibodies against MEK and ERK or their 
phosphorylated forms were used. α/β- Tubulin served as a control for equal 
loading and efficient transfer of the proteins onto the PVDF-membranes. 
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Figure 50: SKBR3 cell line exposed to AS703026 and labelled with phospho-
MEK1,2 (Ser217/221), MEK, phospho-ERK1,2 (Thr202/Tyr204) and ERK1,2 
antibodies.   
Cells were grown in 60mm dishes containing medium with 5% FCS for 24h. The 
cultures were treated for 6h with 0,1µM, 1µM, 5µM 10µM and 20µM AS703026 or with 
the solvent (DMSO) only. Cell lysates were collected as described in Material and 
Methods. α/β-Tubulin was used as a loading control.  
 
Our results indicate that inhibition of MEK1,2 with AS703026 leads to a dose-
dependent increase of pMEK1,2 (Ser217/221). In the absence of the drug the 
level of pMEK1,2 is very low in SKBR3 cells. On the other hand, AS703026 
leads to a strong inhibition of phosporylated ERK1,2, already at the lowest 
inhibitor concentration. These findings indicate, that AS703026 works in the 
same way, compared to the other used MEK1,2 inhibitors. It shows inhibitory 
effects downstream of MEK1,2.  
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Figure 51: T47D exposed to AS703026 and labelled with phospho-MEK1,2 
(Ser217/221), MEK, phospho-ERK1,2 (Thr202/Tyr204) and ERK1,2 antibodies. 
Cells were grown in 60mm dishes containing medium with 5% FCS for 24h. The 
cultures were treated for 6h with 0,1µM, 1µM, 5µM, 10µM and 20µM inhibitor or the 
solvent (DMSO) only. Cell lysates were collected as described in Material and 
Methods. α/β-Tubulin was used as a loading control.  
 
Findings achieved by treatment of T47D with AS703026 revealed that the level 
of pMEK1,2 (Ser217/221) strongly increases at drug concentrations ≥ 1µM. In 
contrast, the level of phosphorylated ERK1,2 strongly decreases at inhibitor 
concentration as low as 0,1µM. Thus, the results obtained with AS703026 are 
similar to those obtained with the two other MEK1,2 inhibitors. In general, all 
three MEK1,2 inhibitors, which did not show any growth inhibitory effects  in 
either cell line, act downstream of MEK1,2 by inhibiting phosphorylation of 
ERK1,2. This reveals that these drugs are potent inhibitors of the MAPK 
cascade but growth of SKBR3 and T47D breast cancer cells appears to be 
largely independent of MAPK activity. 
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3.6 Overcoming the resistance of T47D against pelitinib 
 
Treatment of SKBR3 and T47D with PI3K inhibitors showed some good 
inhibitory effects. Especially in the pelitinib resistant cell line T47D, single 
treatment with PI3K inhibitors was very effective. To see how the growth in both 
cell lines responds to a combined therapy with ErbB and PI3K or MAPK 
inhibitors, combinational growth assays with SKBR3 and T47D cell lines were 
performed.  
 
3.6.1 Combined treatment of SKBR3 or T47D with pelitinib and PI3K 
inhibitors 
 
Single treatment of SKBR3 cells with PI3K inhibitors showed lower growth 
inhibitory effects than in T47D cells, especially with rapamycin. To assess the 
effects of combined therapy with pelitinib and the three PI3K inhibitors Akti-1,2, 
rapamycin and NVP-BEZ 235, combined treatment and growth assay analysis 
was done. SKBR3 cells were treated for 72h with various concentrations of 
gefitinib combined with one concentration of PI3K pathway inhibitors. As 
expected growth assay analysis showed that SKBR3 cells are sensitive against 
pelitinib alone. Combinational treatment with Akti-1,2 does not significantly 
elevate the antiproliferative response (Figure 52). However, combinational 
exposure to pelitinib plus rapamycin or plus NVP-BEZ 235 revealed improved 
inhibitory effects. Figure 53 showed the calculated significance of each 
combination. Combined treatment of SKBR3 cells with 2µM pelitinib and 0,1µM 
rapamycin showed high significance, compared to treatment with pelitinib alone. 
But the significance of combinational exposure of 4µM pelitinib with 0,1µM 
rapamycin revealed lower significance. Moreover exposure of this cell line to 
4µM pelitinib and 0,01µM NVP-BEZ 235 showed high significance compared to 
single treatment with this ErbB inhibitor.        
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Figure 52: Growth curves of pelitinib sensitive cell line SKBR3 treated with 
pelitinib alone or in combination with PI3K inhibitors.      
This cell line was exposed to 0-4µM pelitinib, 0,5µM  Akti-1,2, 0,1µM rapamycin or 
0,01µM NVP-BEZ 235 alone or in combination. Cell growth was analysed by EZ4U. 
Means ± SD, n≥3. 
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Figure 53: Combinational treatment of SKBR3 with pelitinib plus PI3K inhibitors.  
Bars indicate cell numbers (% of control), treatment with pelitinib alone light grey, with 
PI3K inhibitor dark grey and combinational therapy black. Significance was calculated 
using ANOVA followed by Scheffé-Test. * indicates significant difference at p < 0.05 
and ** at p < 0.01. Means ± SD, n≥3. 
 
Single treatment of T47D cells with PI3K inhibitors showed very good growth 
inhibitory effects, especially with the dual mTOR and PI3K inhibitor NVP-BEZ 
235. To assess the effect of both ErbB inhibitor pelitinib and the three PI3K 
inhibitors together, combined therapy with these inhibitors was done. 
Combined growth assay analysis showed that T47D cells are resistant to 
pelitinib alone (Figure 54). However, combined exposure to pelitinib and PI3K 
inhibitors lead to better growth inhibitory effects. Especially exposure to 2µM 
pelitinib combined with 0,1µM rapamycin was very effective. Similarly, treatment 
of pelitinib with Akti-1,2 and NVP-BEZ 235 revealed significant reduction of the 
cell number, compared to an exposure to the ErbB inhibitor alone (Figure 55).  
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Figure 54: Growth curves of pelitinib resistant cell line T47D treated with pelitinib 
alone or in combination with PI3K inhibitors.      
This cell line was exposed to 0-4µM pelitinib, 0,5µM  Akti-1,2, 0,1µM rapamycin or 
0,01µM NVP-BEZ 235 alone or in combination. Cell growth was analysed by EZ4U. 
Means ± SD, n≥3. 
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Figure 55: Combinational treatment of pelitinib and PI3K inhibitors in T47D.   
Bars indicate cell numbers (% of control), treatment with pelitinib alone light grey, with 
the respective PI3K inhibitor dark grey and combinational therapy black. Significance 
was calculated using ANOVA followed by Scheffé-Test. * indicates significant 
difference at p < 0.05 and ** at p < 0.01. Means ± SD, n≥3. 
 
3.6.2 Combined treatment of SKBR3 and T47D with canertinib and PI3K 
inhibitors 
 
Furthermore, a second ErbB inhibitor called canertinib was used in combination 
with PI3K inhibitors, to determine how SKBR3 and T47D cell lines respond to 
another ErbB inhibitor and, moreover, because canertinib is in clinical 
development. Therefore, the same combinational therapies using canertinib and 
PI3K inhibitors were done. Growth assay analysis of SKBR3 cells with 
canertinib alone showed as expected a very good growth inhibitory effect, even 
better than single treatment with pelitinib. Cotreatment with Akti-1,2 did not lead 
to a significant increase of the sensitivity of SKBR3 cells (Figure 56 and 57). 
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Likewise, combined treatment of SKBR3 with canertinib and NVP-BEZ 235 did 
not show a significant decrease of the cell number compared to single treatment 
with canertinib. This result shows that a combination of pelitinib and NVP-BEZ 
235 (Figure 52 and 53) worked better than with canertinib. However, 
cotreatment with 2µM or 4µM canertinib and 0,1µM rapamycin lead to a 
significantly stronger growth inhibitory effect as opposed to canertinib alone, 
which conforms findings achieved when pelitinib was combined with rapamycin.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: Growth curves of SKBR3 treated with canertinib alone or in 
combination with PI3K inhibitors.      
This cell line was exposed to 0-4µM canertinib, 0,5µM  Akti-1,2, 0,1µM rapamycin or 
0,01µM NVP-BEZ 235 alone or in combination. Cell growth was analysed by EZ4U. 
Means ± SD, n≥3. 
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Figure 57: Combinational treatment of canertinib and PI3K inhibitors in SKBR3.   
Bars indicate cell numbers (% of control), treatment with canertinib alone light grey, 
with the respective PI3K inhibitor dark grey and combinational therapy black. 
Significance was calculated using ANOVA followed by Scheffé-Test. * indicates 
significant difference at p < 0.05 and ** at p < 0.01. Means ± SD, n≥3. 
 
In growth assay analysis (Figure 58) pelitinib resistant T47D cells were cross-
resistant to canertinib alone. Combinational therapy using this ErbB inhibitor 
together with PI3K inhibitors lead to highly significant growth inhibition versus 
single canertinib treatment (Figure 59). The effects for canertinib were even 
more pronounced than that seen after pelitinib/PI3K inhibitor cotreatment in this 
cell line. 
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Figure 58: Growth curves of T47D treated with canertinib alone and in 
combination with PI3K inhibitors.      
This cell line was exposed to 0-4µM canertinib, 0,5µM  Akti-1,2, 0,1µM rapamycin or 
0,01µM NVP-BEZ 235 alone or in combination. Cell growth was analysed by EZ4U. 
Means ± SD, n≥3. 
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Figure 59: Combinational treatment of canertinib and PI3K inhibitors in T47D.  
Bars indicate cell numbers (% of control), treatment with canertinib alone light grey, 
with the respective PI3K inhibitor dark grey and combinational therapy black. 
Significance was calculated using ANOVA followed by Scheffé-Test. * indicates 
significant difference at p < 0.05 and ** at p < 0.01. 
 
Cotreatment of ErbB inhibitor resistant T47D cells with both ErbB drugs and 
with the three PI3K inhibitors, respectively, significantly reduced the growth and 
therefore the resistance of the cells against pelitinib and canertinib. In contrast, 
the ErbB inhibitor sensitive cell line SKBR3 did not show such high growth 
inhibitory effects in combinational therapy.  
 
3.6.3 Cotreatment of pelitinib and MAPK inhibitors 
 
There were no growth inhibitory effects obtained in previous growth analysis 
done with MAPK inhibitors in SKBR3 and T47D cells. Nevertheless, we 
wondered, if there is any improvement, when MAPK- and ErbB drugs are 
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combined. Therefore, growth assay analysis with pelitinib combined with 
AZD6244 or U0126 combined was done. 
Cotreatment of SKBR3 with pelitinib and with AZD6244 or with U0126 failed to 
show improved growth inhibitory effects (Figure 60 and 61). Therefore, as 
expected, neither MAPK inhibitor could improve the effect caused by pelitinib. 
Similar analyses of treatment in T47D cells, also failed increase growth 
inhibition by pelitinib (Figure 62 and 63).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: Growth curves of SKBR3 treated with pelitinib alone and in 
combination with two MAPK inhibitors.        
This cell line was exposed to 0-8µM pelitinib, 10µM AZD6244 or 40µM U0126 alone or 
in combination. Cell growth was analysed by EZ4U. Means ± SD, n≥3. 
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Figure 61: Combinational treatment of pelitinib and MAPK inhibitors in SKBR3.   
Bars indicate cell numbers (% of control), treatment with pelitinib alone light grey, with 
the respective MAPK inhibitor dark grey and combinational therapy black. Significance 
was calculated using ANOVA followed by Scheffé-Test. **indicates significant 
difference at p < 0.01. 
 
 
 
 
 
 
 
 
 
 
Figure 62: Growth curves of T47D treated with pelitinib alone and in combination 
with two MAPK inhibitors.      
This cell line was exposed to 0-4µM pelitinib, 10µM AZD6244 and 40µM U0126 alone 
or in combination. Cell growth was analysed by EZ4U. Means ± SD, n≥3. 
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Figure 63: Combinational treatment of pelitinib and MAPK inhibitors in T47D 
cells.  
Bars indicate cell numbers (% of control), treatment with pelitinib alone light grey, with 
the respective MAPK inhibitor dark grey and combinational therapy black. (Significance 
was not calculated, because data set was not relevant) Means ± SD, n≥3. 
 
 
3.6.4 Cotreatment of SKBR3 and T47D cells with canertinib and MAPK 
inhibitors  
 
To determine how a combined treatment of SKBR3 and T47D with canertinib 
and MAPK inhibitors affects the growth of these cell lines, growth assays with 
these drugs were performed. As expected, this cotreatment did not show any 
increased growth inhibitory effects, neither with AZD6244 nor with U0126 
(Figure 64 and 65) in the SKBR3 cell line. Moreover, such a combinational 
treatment revealed the same result in T47D cell line (Figure 66 and 67). 
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Figure 64: Growth curves of SKBR3 treated with canertinib alone and in 
combination with two MAPK inhibitors.      
This cell line was exposed to 0-4µM canertinib, 10µM AZD6244 or 20µM U0126 alone 
or in combination. Cell growth was analysed by EZ4U. Means ± SD, n≥3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 65: Combinational treatment of SKBR3 cells with canertinib and MAPK 
inhibitors.  
Bars indicate cell numbers (% of control), treatment with canertinib alone light grey, 
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with the respective MAPK inhibitor dark grey and combinational therapy black. 
Significance was calculated using ANOVA followed by Scheffé-Test. ** indicates 
significant difference at p < 0.01. Means ± SD, n≥3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: Growth curves of T47D treated with canertinib alone and in 
combination with two MAPK inhibitors.      
This cell line was exposed to 0-4µM canertinib, 10µM AZD6244 and 20µM U0126 
alone or in combination. Cell growth was analysed by EZ4U. Means ± SD, n≥3. 
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Figure 67: Combinational treatment of T47D cells with canertinib and MAPK 
inhibitors. 
Bars indicate cell numbers (% of control), treatment with canertinib alone light grey, 
with the respective MAPK inhibitor dark grey and combinational therapy black. 
(Significance was not calculated, because dataset was not relevant). Means ± SD, n≥3. 
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4. Discussion          
 
Treatment of breast cancer includes surgery, radiotherapy and application of 
cytotoxic or cytostatic inhibitors of tumor growth. Unfortunately, however, the 
death rate of breast cancer has not significantly decreased in recent years. This 
appears to be the result of rising incidence or resistance to therapy. Therefore, 
development of new drugs is very important (Dickson et al., 2006). A hallmark 
of breast cancer is its great heterogenity. Moreover, the ErbB receptor family 
plays a crucial role in the development of this form of cancer. This 
transmembrane receptor family, which bears tyrosine kinase activity, consists of 
four homologous members (EGFR/ErbB1/Her1, ErbB2/Her2/neu, ErbB3/Her3 
and ErbB4/Her4). EGFR is deregulated in a number of human malignancies. 
ErbB2 shows overexpression in 20-30% of breast cancer and correlates with an 
increased resistance to hormone-based therapy. Overexpression of EGFR is 
often associated with poor survival and chemoresistance. Therefore, EGFR has 
become an important target for anticancer drug development. (Karamouzis et 
al., 2006; Hermanto et al., 2000 and Laheru et al., 2008). The monoclonal 
antibody trastuzumab (Herceptin) is being used to treat patients with ErbB2 
overexpressing breast cancer. It provides good clinical benefits in such patients, 
but patients with advanced disease, who initially responded to this antibody 
develop resistance against this drug (Eichhorn P. et al., 2008). Moreover, long-
term treatment using reversible EGFR inhibitors such as gefitinib and erlotinib 
also causes resistance. Pelitinib (EKB-569) reveals retained inhibitory activity 
against cancers that became resistant against erlotinib and gefitinib, because it 
is an irreversibly acting inhibitor, which binds to the target proteins EGFR and 
ErbB2 by covalent interaction (Wissner et al., 2008).   
In cancer a high frequency of mutations in the downstream signalling pathways 
of ErbB, the RAS-RAF-mitogen-activated protein kinase (MAPK)/extracellular 
signal-regulated kinase (ERK) kinase (MEK)-ERK and phosphoinositide 3-
kinase (PI3K)-PTEN-AKT signaling pathway, occur. They play central roles in  
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the signal transduction networks, by promoting tumor initiation and tumor 
progression. Mutations of RAS, RAF, PI3KCA, AKT and PTEN and, moreover, 
amplification of AKT can be found in many human malignancies. Targeting 
pathways downstream, could lead to greater therapeutic efficacy than upstream 
inhibition, because there exists multiple upstream inputs (Mirzoeva et al., 
2009).Therefore, these pathways provide a number of promising molecular 
targets for cancer therapy. Hence, a new generation of PI3K inhibitors is 
emerging, which hopefully can overcome the problems of ErbB drug resistance. 
For example, NVP-BEZ 235, a dual mTOR and PI3K inhibitor, or Akti-1,2, a 
selective AKT1 and AKT2 inhibitor, show good inhibitory effects in breast 
cancers, which are depending on the PI3K pathway (Serra et al., 2008; She et 
al., 2008). Moreover, there are also mitogen activated protein kinase pathway 
inhibitors in use. Oncogenic mutations in RAS lead to deregulation of several 
effector pathways that control cell proliferation and survivial. Deregulation of 
MAPK pathway often occurs through KRAS or BRAF mutations. These findings 
validate this pathway as a therapeutic target in breast cancer, but treatment with 
MEK inhibitors have shown only limited antitumor activity. A possible reason for 
that could be that the PI3K pathway activation strongly influences the sensitivity 
of RAS mutant cells to MEK inhibitors. Activating mutations in PIK3CA reduce 
the sensitivity of MEK inhibition whereas PTEN mutations cause complete 
resistance, which could be avoided by combined blockade of the MAPK and the 
PI3K pathway (Wee et al., 2009 and Mirzoeva et al., 2009).  
 
4.1. Responsiveness of different breast cancer cell lines to 
ErbB inhibition 
 
In a previous study (Brünner-Kubath et al., in press) we have shown that the in 
vitro growth of SKBR3 breast cancer cells can be blocked by exposure to the 
irreversible  EGFR/ErbB2 inhbitor pelitinib, whereas T47D cells were found to 
be resistant to this drug. To examine how the growth of other breast cancer cell 
 Discussion 
 
 
105 
 
lines responds to a treatment with pelitinib, a panel of cancer cells including 
T47D and SKBR3 was treated with this drug. Concordant to the results 
achieved in previous assays, T47D cells displayed distinct higher resistance 
than SKBR3 cells. Moreover, we found additional pelitinib resistant (MDA-MB 
231 and MCF7) and sensitive (BT474) breast cancer cell lines. The two pelitinib 
sensitive cell lines reveal a high ErbB2 expression level which is not displayed 
by the other tested cell lines and therefore a possible reason for a higher 
sensitivity (Brünner-Kubath et al., in press). On the other hand although ErbB2 
is overexpressed in 20-30% of invasive breast carcinomas, the monoclonal 
antibody trastuzumab which specifically targets the extracellular domain of 
HER2 reveal only limited efficiency because of primary resistance or acquired 
resistance. Moreover, ErbB1, -3 or -4 do not correlate with sensitivity against 
pelitinib of these cell lines (Brünner-Kubath et al., in press; Eichhorn P. et al, 
2008). Downstream signalling effects of pelitinib revealed that the pelitinib 
resistant cell line MCF7 responds with increasing levels of pAKT and pERK1/2. 
Maybe this cell line responds in the same way as T47D cells to the inhibitor, 
because both exhibit a mutation in the catalytic subunit p110α of the PI3K 
(PIK3CA). PI3K signals through AKT and other downstream effectors and 
represents a key mechanism of transducing proliferative and antiapoptotic 
signals. This pathway is activated in many breast cancer cell lines and, 
moreover, activating mutations in the catalytic subunit of p110-α occur in 25-
30% of breast tumors, alike in our tested cell lines T47D which harbour a 
H1047R and MCF7 revealing a E545K mutation. Conversely, BT474 cells 
respond very sensitive to pelitinib, although they harbour a K111N mutation in 
PIK3CA. However, BT474 cells also show an ErbB2/Her2 amplification, 
whereas T47D express low levels of ErbB2 (Hoeflich et al., 2009 and She et al., 
2008). Moreover, BT474 is the only tested cell line harbouring both, PIK3CA 
mutation and overexpression of ErbB2. She et al.,(2008) found out that 
activation of the PI3K/AKT pathway through ErbB2 signalling plays an important 
role in mediation the transformed phenotype in breast cancer with ErbB2  
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overexpression. Interestingly, MDA-MB-231 cells, which do not have a PIK3CA  
mutation, show extremely low levels of phosphorylated AKT in the untreated 
control. Therefore, we hypothesize that the MAPK pathway could be more 
important in this cell line, because they reveal a high ERK1/2 phoshporylation 
level in the untreated control and, moreover, they harbour a KRAS mutation 
(Hoeflich et al., 2009). But growth analysis with MEK1/2 inhibitors revealed no 
significant response to the growth inhibitory effects of these drugs. Therefore, 
our hypothesis could not be confirmed. 
 
4.2. Fundamental ErbB downstream signalling pathway of 
SKBR3 and T47D  
 
4.2.1. Examination of the growth inhibitory effects of PI3K and MAPK 
pathway inhibitors 
 
Previous findings from Brünner-Kubath et.al (in press) showed that pelitinib 
resistance is associated with drug-refractory phosphorylation (activation) of 
AKT, whereas the phosphorylation of the MAPKs Erk1/2 does not correlate with 
pelitinib resistance or sensitivity. Both, the PI3K and the MAPK systems are 
major ErbB downstream signalling pathways. Treatment of SKBR3 and T47D 
with an mTOR inhibitor (rapamycin) exerted a higher growth inhibitory effect on 
T47D relative to SKBR3 cells. This may be caused by an activating mutation in 
the catalytic p110 subunit of PI3K (PIK3CA) in T47D, whereas SKBR3 cells 
express wild type PIK3CA (Crowder et al., 2009; She et al., 2008). mTOR 
signals through two distinct complexes. The first one is mTORC1, also called 
RAPTOR, which is composed of regulatory- associated protein of mTOR 
(RAPTOR), mLST8 also known as GβL and the proline-rich AKT substrate 
(PRAS). RAPTOR positively regulates mTOR, but PRAS acts as an inhibitor of 
MTR kinase activity in a phosphorylation-dependent manner. The PI3K and 
MAPK signalling pathways regulate the mTORC1 function through tuberous 
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sclerosis complex 2 (TSC2). The second one is mTORC2, also called RICTOR, 
which is composed of mLST8, rapamycin-insensitive companion of mTOR 
(RICTOR) and SIN1 or RICTOR. RICTOR leads to the full activation of the AKT 
kinase through phosphorylation of Ser(473). Notably, rapamycin inhibits only 
mTORC1, but not mTORC2 (Carracedo et al., 2008). Therefore a dual inhibitor 
of mTOR and PI3K called NVP-BEZ 235 was used. Antiproliferative effects of 
NVP-BEZ 235, which blocks mTORC1, mTORC2 and PI3K (Serra et al., 2008), 
were analysed in growth asssays. This inhibitor acted as a strong growth 
inhibitor in both cell lines, especially in T47D cells. These results go along with 
the finding of Brachman et al., (2009), who showed that a treatment of cell lines 
with PIK3CA mutation or ErbB2 amplification with NVP-BEZ 235 leads to 
induced cell death. In contrast, the drug is inefficient in inhibiting growth of cells, 
which harbour KRAS mutations or loss of PTEN function. Our two cell lines 
show PIK3CA mutation (T47D) or Her2 amplification (SKBR3), but neither 
KRAS nor PTEN loss (Hoeflich et al., 2009 and She et al., 2008).    
   
Growth assay analysis with a special AKT inhibitor called Akti-1,2 show good 
inhibitory effects in both cell lines, but in T47D it was less efficient than NVP-
BEZ 235 or rapamycin. This result goes along with the finding of Vasudevan et 
al. (2009), where they uncovered an AKT-independent signal, which is active in 
many cancer cell lines possessing a PIK3CA mutation, so that AKT inhibition 
does not have any growth inhibitory effect. Moreover, they suggested that an 
inhibition of PI3K or downstream effectors could be more effective than an 
inhibition of AKT. Usage of theses different PI3K inhibitors showed that the 
PI3K pathway must be important for both cell lines, because they respond 
sensitive to their exposure. Treatment of these two cell lines with MEK1,2 
inhibitors showed no growth inhibitory effects, neither on SKBR3 nor on T47D 
cells. Mirzoeva et al. (2009) demonstrated that MEK1,2  inhibitors exhibit only 
limited antitumor activity in luminal breast cancer cell lines like T47D and  
SKBR3. Moreover, they suggested that luminal breast cancer cell lines depend  
 
  Discussion 
 
 
108 
 
more on the PI3K than on the MAPK-pathway, which is supported by the 
preferential occurrence of PI3K mutations in this subtype of breast cancer cell 
lines. Furthermore, they found that the PI3K pathway becomes activated in 
response to MEK inhibition, through a negative MEK- EGFR- PI3K feedback 
loop, which therefore limits the efficiency of the MEK1,2 inhibitors.  
 
4.2.2. Examination of the downstream signalling effects of PI3K and MAPK 
pathway inhibitors   
 
Our results achieved in growth assay analysis with SKBR3 and T47D indicate 
that the PI3K pathway seems to play more important role in growth regulation of 
both cell lines than the MAPK pathway. We then wanted to examine not only 
the response of growth inhibition, but we also wanted to get a more precise 
information on how these inhibitors exactly do affect the two ErbB downstream 
signalling pathways. As expected the mTOR inhibitor rapamycin caused an 
immediate reduction of the S6 phosphorylation level in SKBR3 and T47D cells, 
because S6 is located downstream of mTOR. But this inhibitor showed minor 
inhibitory effects of the PI3K and MAPK pathway, except at high drug 
concentrations. This finding goes along with a study from Carracedo et al. 
(2008), who found that there exists an mTORC1-MAPK feedback loop. 
Normally, mTORC1 activation leads to PI3K and MAPK inhibition through a 
negative feedback loop stemming from S6K1 (p70 ribosomal protein S6 kinase 
1). Consequently, rapamycin-mediated inhibition of mTORC1 results in 
hyperactivation of PI3K, and also activates the MAPK pathway. This finding 
explains the increasing level of phosphorylated AKT and ERK1,2 seen in our 
Western blotting analysis after rapamycin treatment. It is known that selective 
inhibition of mTOR can abrogate a negative feedback loop, which usually keeps 
phosphorylation of AKT in check, thereby causing a paradoxic upregulation of 
pAKT (Thr308) levels (Mirzoeva et al., 2009).       
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The dual PI3K and mTOR inhibitor NVP-BEZ 235 inhibits class 1 PI3K catalytic 
activity by competing at its ATP-binding site and, compared to rapamycin, which 
inhibits only mTORC1, this drug shows inhibitory effects on both, mTORC1 and 
mTORC2 (Serra et al., 2008; Carracedo et al., 2008). Our findings interestingly 
showed that low concentrations of NVP-BEZ 235 inhibited only pAKT (Ser473), 
but not pAKT (Thr308), in T47D cell lines. This result could be explained by a 
differentially phosphorylation of them. AKT (Ser473) becomes directly 
phosphorylated by mTORC2, but in contrast, AKT (Thr308) becomes 
phosphorylated through PI3K, in which PDK1 is an essential link (Qian Yang et 
al., 2006). Moreover, NVP-BEZ-235 shows a higher affinity to mTOR than to 
PI3K (Serra et al., 2008). Therefore mTOR becomes inhibited at low drug 
concentrations, but not PI3K. Low drug concentrations inhibit mTORC2, which 
lead to an inhibition of the phosphorylation of AKT (Ser473). But, the blockade 
of mTORC1, through NVP-BEZ 235, decreases mTOR-dependent negative 
feedback-regulation of PI3K and therefore of PDK1, thus stimulates the 
phosphorylation of AKT (Thr308) (Huang et al., 2009). On the other hand, high 
inhibitor concentrations result in downregulation of both, AKT (Ser473) and AKT 
(Thr308) phosphorylation, because NVP-BEZ 235 inhibits both mTOR and 
PI3K. Constitutive phosphorylation of S6 ribosomal protein is quite high in 
control cells and was decreased by the drug at the lowest inhibitor 
concentration in SKBR3 and at a slightly higher drug concentration in T47D 
cells. This is compatible with the notion that mTOR inhibition occurs at lower 
drug concentrations, whereas both mTOR and PI3K become inhibited at higher 
concentrations of NVP-BEZ 235, because S6 ribosomal protein is located 
downstream of mTOR (Serra et al.,2008). Moreover, NVP-BEZ 235 leads to an 
increase of the phosphorylation level of ERK1,2. This finding goes along with 
results we achieved with rapamycin, where we suggested that there exists, a 
negative mTORC1-MAPK feedback loop. Inhibition of mTORC1 through NVP-
BEZ 235 and rapamycin results in an activation of the MAPK pathway, because 
mTORC1 normally leads to MAPK inhibition through a negative feedback loop  
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based from S6K1. But inhibition of mTOR leads to an increase of this pathway 
(Mirzoeva et al., 2009). Direct inhibition of AKT through Akti-1,2 in SKBR3 and 
T47D cells is not as efficient as the other pathway inhibitors used  (rapamycin 
and NVP-BEZ 235). Previous studies showed that breast cancer cell lines, 
which possess a PIK3CA mutation, exhibit only minimal AKT activation. 
Therefore, a diminished reliance on AKT for anchorage independent growth 
was found. These cells seem to use a signalling pathway that is independent of 
AKT. Therefore, inhibition with Akti-1,2 does not lead to a significant inhibitory 
effect at low drug concentrations (Vasudevan et al., 2009).    
     
Our growth assay analysis done before showed no growth inhibitory effect of 
MEK1,2 inhibitors in SKBR3 and T47D cells. We therefore wanted to examine if 
these inhibitors actually do inhibit the MAPK cascade in these cells and 
performed Western blot analyses in cells exposed to the MEK1,2 drugs 
AZD6244, U0126 or AS703026. These inhibitors showed good inhibition of 
phosphorylated ERK1,2 but no significant inhibitory effects on MEK1,2 
phosphorylation. This finding suggests that these three inhibitors act 
downstream of MEK by inhibiting phosphorylated ERK1,2. Moreover, these 
results together with these obtained from growth assays indicate that MEK1,2 
inhibitors are not adequate for inhibition of growth of these cell lines. 
Furthermore, these results showed that the MAPK pathway does not seem to 
be important for growth regulation in both cell lines and, therefore, inhibition of 
only this pathway is not enough to overcome the resistance of T47D cells 
against pelitinib. Furthermore Hoeflich et al., (2009) underline the notion that 
MEK inhibition in luminal breast cancer cell lines (SKBR3 and T47D) does not 
have any significant growth inhibitory effect, despite the fact that they also 
achieved a strong reduction of the pERK1,2 level in luminal breast cancer cells. 
All our data achieved in growth assay and Western blotting analysis with PI3K 
and MAPK pathway inhibitors suggested that the PI3K pathway plays a more 
important role in growth regulation of SKBR3 and T47D cells. Therefore, 
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inhibition of this pathway could be a good approach to overcome the resistance 
of T47D cells against the ErbB inhibitor pelitinib.  
 
4.3. Combined therapy in SKBR3 and T47D cell lines 
 
Here we demonstrated that treatment of SKBR3 and T47D with PI3K inhibitors 
leads to good growth inhibitory effects, especially in the pelitinib resistant cell 
line T47D. Therefore, we wondered which effect a cotreatment using the ErbB 
inhibitors pelitinib or canertinib together with the three different PI3K inhibitors 
may exert on the growth of SKBR3 and T47D cells. Canertinib as a second 
ErbB inhibitor was used to see how these cell lines respond to another drug 
than pelitinib and, moreover, because it is in clinical trials. Combinational 
therapy of SKBR3 cell lines with PI3K inhibitors and pelitinib showed a good 
elevation of the cellular sensitivity against pelitinib. Treatment with pelitinib 
together with rapamycin or with NVP-BEZ 235 showed high significant growth 
inhibition compared to pelitinib single treatment. Single treatment with the ErbB 
inhibitor canertinib leads to very good growth inhibition, but only treatment with 
rapamycin showed significantly elevated effect.    
Cotreatment of T47D cells with pelitinib and rapamycin revealed a highly 
significant growth inhibition compared to exposure to pelitinib alone. Therapy 
with this ErbB inhibitor and Akti-1,2 or with NVP-BEZ 235 revealed a significant 
growth reduction. As expected, single therapy of T47D cells with canertinib was 
inefficient. However, elevated sensitivity was observed by combined exposure 
of the cells to canertinib and Akti-1,2, rapamycin or NVP-BEZ 235. These 
observations revealed that rapamycin, Akti-1,2 and NVP-BEZ 235 increased the 
antiproliferative effects of pelitinib and canertinib in ErbB resistant T47D cells. 
This effects seems to be dependent on inhibition of mTOR, because rapamycin, 
which inhibits mTOR shows growth inhibitory effects like other drugs inhibiting 
PI3K and mTOR (NVP-BEZ 235) or Akt (Akti-1,2). Treatment with ErbB and 
PI3K inhibitors is very effective and, moreover, able to overcome the resistance 
  Discussion 
 
 
112 
 
of T47D against the two ErbB inhibitors. In contrast cotreatment with ErbB 
inhibitors and MEK1,2 inhibitors does not improve the growth inhibitory effect. 
Hoeflich et al., (2009) found that basal like breast cancer cell lines, which lack 
expression of ErbB2/Her2, respond sensitive to the inhibitory effects of MEK 
inhibition, in contrast to luminal breast cancer cell lines. They also found that the 
tumor suppressor PTEN is a negative predictive factor for response to MEK 
inhibition. Moreover, they showed that the combination of MEK and PI3K 
inhibitors lead to enhanced efficacy. Our tested cell lines are of luminal origin 
and showed that the combined therapy with ErbB2 and PI3K inhibitors yield 
strong growth inhibitory effects and, moreover, efficiently overcomes cellular 
resistance against ErbB-inhibitory drugs. 
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